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Abstract 
A lot of materials exhibit novel properties when scaled down to nanoscale. Here we 
explore nanoelectrode arrays (NEAs) and nanoparticles in the application of high performance 
biosensors. 
We have developed an electrochemical (EC) method for measuring the activity of 
proteases using vertically aligned carbon nanofiber (VACNF) NEAs. VACNFs were grown on 
conductive substrates and encapsulated in SiO2 matrix. After polishing and plasma etching, 
controlled VACNF tips are exposed to form an embedded NEA. Tetrapeptides specific to cancer-
mediated proteases are covalently attached to the exposed tip, with a ferrocene (Fc) moiety 
linked at the distal end. The redox signal of Fc can be measured with AC voltammetry (ACV) at 
~1 kHz frequency, showing distinct properties from macro-electrodes due to VACNF’s unique 
interior structure. The enhanced ACV properties enable the kinetic measurements of proteolytic 
cleavage of the surface-attached tetrapeptides by proteases. The well-defined regular VACNF 
NEAs by e-beam lithography show a much faster kinetics for cathepsin B proteolysis.  
This EC method was further applied in whole lysate of human breast tissue and breast 
cells. The detected protease activity was found increased in cancer cells, with the metastatic 
cancer cell lysate showing the highest cathepsin B activity. The results indicated the potential of 
this technique as a portable multiplex electronic device for cancer diagnosis and treatment 
monitoring through rapid profiling of the activity of specific cancer-relevant proteases. 
In another exploratory study, we modified nanoparticles with luminol and viral nucleic 
acid to develop chemiluminescence (CL) biosensors for blood-borne pathogens. Luminol-labeled 
10-nm-diameter gold nanoparticles (GNPs) served as a nanocarrier for enhancing CL signal. The 
CL signal can be observed over 8 orders of magnitude variations in GNP concentration. Using 
  
the same number of particles, luminol-labeled 30-nm-diameter latex beads showed ~3 orders of 
magnitude higher CL compared to 10-nm-diameter GNPs. Hybridization of target H1N1 nucleic 
acid on the latex beads and probe nucleic acid on the glass or optical fiber surface has been 
achieved. This assay will be incorporated into a simple hand-held device for routine assays in 
hospitals and clinics, or for large-scale screening of human populations as diagnostic tools to 
identify specific viral strains.  
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Preface 
This dissertation consists of the following major sections:  
Chapter 1 – A brief introduction of the principle of biosensors and the use of nanoscale 
materials for biosensing application. Some traditional biosensing techniques for proteases and 
DNA detection are discussed. This forms the basis and motivation to develop protease and DNA 
biosensor based on nanomaterials.  
Chapter 2 – A brief description of the procedures of the fabrication and characterization 
of vertically aligned carbon nanofiber (VACNF) nanoelectrode arrays (NEAs). General 
experimental details for protease detection are also described.  
Chapter 3 – An accepted paper, published in Journal of Physical Chemistry C1. This 
chapter demonstrates that high-frequency ACV can be applied on embedded VACNF NEAs to 
measure the redox reaction of Fc attached to the exposed CNF tip through a tetrapeptide and a 
linker molecule. The kinetics of proteolysis of the surface-attached peptides by cancer-related 
proteases, legumain and cathepsin B, is measured and analyzed with a heterogeneous Michaelis-
Menten model to derive the “specificity constant” kcat/Km. This is the first example of the use of 
VACNF NEAs on protease activity study. The study demonstrates that these VACNF NEA 
based electrochemical enzymatic biosensors can be potentially developed into portable multiplex 
electronic devices for rapid cancer diagnosis and treatment monitoring.  
Chapter 4 – An accepted paper, published in Biosensors and Bioelectronics2. This chapter 
further investigates the kinetics of cathepsin B activity in complex tissue lysates. A 
normalization algorithm is introduced to extract the proteolysis signal from the largely varied 
raw data, which enabled the consistent comparison of the results from the kinetic study. 
Moreover, the study of using regular VACNF NEAs fabricated with precise e-beam lithography 
xxxiv 
exhibits faster kinetics of cathepsin B proteolysis, illustrating the potential for further improving 
detection sensitivity by using this EC technique. 
Chapter 5 – A manuscript submitted to Nanomedicine: nanotechnology, biology and 
medicine. This chapter brings the application of EC biosensor based on VACNF NEAs to a 
further stage – study of cathepsin B activity in breast cell lysates and the specificity study by 
using cathepsin B inhibitor GC-373. It is illustrated that this EC method is a reliable tool to 
measure the proteolytic kinetics and quantify the protease activity in complex breast cell lysates. 
The activity of cathepsin B was found to increase from normal to cancer cell lysates. Moreover, 
the clear inhibition effects by GC-373 compound indicate that this method may also be used as 
an effective technique for inhibitor screening in the complex biological samples.  
Chapter 6 – Part of the content of this chapter is from an accepted paper, published in 
Analyst
3
. This chapter discusses the development of ultrasensitive blood-borne pathogen 
biosensor based on nanoparticles using chemiluminecence (CL) method. It describes the methods 
of modification of gold nanoparticles and latex beads with luminol and/or viral nucleic acid and 
the immobilization of nanoparticles on the optical fibers through nucleic acid hybridization. CL 
measurements are conducted by commercial luminometer in 96-well plates. This work explores a 
new biosensor direction for future studies.  
Finally, chapter 7 summarizes the major findings of the work and discusses the future 
direction for both the EC protease biosensor and CL pathogen biosensor.  
1 
Chapter 1 - Introduction 
 1.1 Principles and significance of biosensors 
Principles 
Biosensors are analytical devices incorporating a biological sensing element connected to 
physicochemical transducers that generate measureable signals proportional to the concentration 
of a specific chemical or a set of chemicals (Figure 1.1).
4-9
 Based on the type of the receptor, 
biosensors can be classified as enzymatic biosensors, genosensors, immunosensors, etc. 
Biosensors can also be divided into several categories according to the type of the transducer. 
Three of the most common transduction principles for sensing include mass, electrochemical and 
optical detection. Mass biosensor can produce a signal depending on the mass of the chemicals 
that interact with the sensing film. Piezoelectric biosensor is the most common sensor in this 
class, which is based on that the resonant frequency of an oscillating piezoelectric crystal can be 
affected by a small change in mass at the crystal surface.
10
 Electrochemical (EC) sensor is to use 
electrodes to measure the electrochemical changes that occur when chemicals interact with the 
sensing surface. Transduction of the chemical signal into an electrical signal can be done by 
amperometry, voltammetry, potentiometry, impedance spectroscopy etc. Optical sensors often 
involve optical fibers to direct light to the sensing film. The optical signals can be absorbance, 
fluorescence (FL), chemiluminescence (CL), surface plasmon resonance or light reflectivity. For 
biosensor development, there are a number of aspects to be considered, such as the generation of 
transduction signal (increase of signal, decrease of noise, etc.), sensor design (sample injection 
and drainage, reduction of sample consumption, reduction in detection time, etc.), surface 
immobilization (analyte binding efficiency, elimination of non-specific binding, etc.), binding 
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format (direct binding, sandwich-type binding, etc.), and data analysis (extraction of information 
regarding analyte concentration, binding kinetics, etc.).
11
  
 
Figure 1.1 Schematic showing the principle and main components of a biosensor.  
 To characterize the sensor performance, sensitivity, detection limit (DL) and linear 
concentration range are important parameters to consider. Sensitivity is defined as the change of 
the magnitude of the sensor transduction signal in response to the change of the analyte.
11
 DL 
can be deduced by the ratio of the noise in the transduction signal and the sensitivity. It is usually 
desired to increase sensitivity and decrease DL as much as possible. Finally, the linear 
concentration range is determined by the lower and upper limits of the quantification.  
The recent development in nanotechnology has generated a number of new materials and 
devices that have desirable properties and useful functions for numerous biosensor 
applications.
12-15
 Various kinds of nanomaterials, such as carbon nanotubes (CNTs)
16-18
, gold 
nanoparticles (GNPs)
19-20
, magnetic nanoparticles
21
 and quantum dots
22-23
 have been broadly 
applied in biosensor development due to their unique physical, chemical, mechanical, optical and 
magnetic properties. The high surface to volume ratio of nanomaterials commonly leads to 
remarkable enhancement of sensitivity and specificity of the detection.  
  
3 
Significance 
Although great advances have been made against cancer, in 2012 alone, 8.2 million 
people worldwide died of cancer.
24
 This number will rise to 14.6 million cancer deaths in 2035 if 
no significant advances in cancer prevention, detection, and treatment is made.
25
 Cancer is also 
one of the costliest diseases globally. It has been estimated that 13.3 million new cases of cancer 
in 2010 have cost $290 billion worldwide. Thus, there is an urgent need for more efficient and 
economic prevention and treatment approaches due to the increasingly economic and personal 
burden of cancer. Regarding cancer research, biosensors have been intensively studied and found 
in many applications in early diagnosis and screening of cancers. For example, Yuan et al. 
reported clinical diagnostic application of the localized surface plasmon resonance (LSPR) 
biosensor in ovarian cancer. The results of detection of biomarker human epididymis secretory 
protein 4 demonstrated that this LSPR biosensor can serve as an effective alternative for the 
clinical serological diagnosis of ovarian cancer with fast detection speed, good specificity, 
effective reproducibility and long-term stability.
26
 Jin et al. developed an EC biosensor based on 
label-free graphene for detection of cancer biomarker and carcinoembryonic antigen.
27
 The high 
sensitivity, good specificity, ease of fabrication and operation plus the short analysis time make 
this EC biosensor a promising candidate for the clinical diagnosis of cancer. 
Blood-borne pathogens are microorganisms such as viruses or bacteria in human blood or 
body fluids that cause disease in people. The most common ones are hepatitis B, hepatitis C and 
human immunodeficiency virus (HIV) which causes acquired immune deficiency syndrome 
(AIDS). In 2009, close to 2 million people died from AIDS worldwide and the epidemic 
continues to grow rapidly. The United Nations’ UNAIDS office and World Health Organization 
(WHO) estimate that in certain areas of Africa over 33% of adults are living with HIV. Millions 
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of children have been orphaned in Africa due to the epidemic. More than 34 million people 
worldwide are infected with HIV. The epidemic is also spreading rapidly in Eastern Europe and 
Asia.
28
 Hepatitis C virus can cause hepatitis C, a liver disease. 130-150 million people globally 
are diagnosed with chronic hepatitis C infection. 350,000 to 500,000 people die each year 
worldwide due to hepatitis C-related liver diseases. Unlike hepatitis B disease, there is currently 
no vaccine for hepatitis C.
29
 Early and accurate diagnosis of those diseases is critical in 
increasing the survival rate and enhancing patients’ life quality. Various biosensing techniques 
for blood-borne pathogens detection with high sensitivity have been extensively studied and 
successfully applied. Based on antigen/antibody-binding affinity, there are pathogen sensing 
techniques such as enzyme immunoassay (EIA)
30
 and enzyme-linked immunosorbent assay 
(ELISA)
31
. Pathogens can also be detected through their unique nucleic acid chain, such as 
deoxyribonuleic acid (DNA) and ribonuleic acid (RNA). DNA sensing methods include 
polymerase chain reaction (PCR) and DNA microarray.
32
 Depending on the type of the output 
signal, DNA microarray can also be classified into several categories, such as fluorescence and 
colorimetric methods,  Raman spectroscopy
33
, electrochemical method
14
, SPR spectroscopy
34
 
etc. Electrochemical biosensor for rapid, convenient and cost-effective pathogen detection has 
also been reported.
35
 Both immunoassay and nucleic acid hybridization can be applied on 
electrochemical platforms. 
 1.2 Nanoscale materials for biosensing: advantages and challenges 
When scaled down to nanoscale, a lot of materials exhibit novel properties which cannot 
be extrapolated from their bulk behavior.
36
 In recent years, with the development of 
nanotechnology and the discovery of the nanomaterials with novel properties, the application of 
nanoscale materials in biosensor field has advanced greatly. For example, gold nanoparticles 
5 
(GNPs) have strong absorption of the incident light in the UV-vis range when the amplitude of 
electron oscillation around the particle surface reaches maximum at a specific frequency– an 
unique phenomenon called surface plasmon resonance (SPR).
37
 SPR frequency can be affected 
by the size and shape of nanoparticles, surface charges, dielectric constant of surrounding 
medium etc. SPR biosensors based on GNPs are one of the most advanced label-free optical 
biosensor technologies and have great potentials in numerous fields, such as environmental 
monitoring, disease diagnosis and food safety.
38-39
 GNPs are also biocompatible with 
biomolecules, thus greatly increasing the number of biomolecules immobilized on the surface of 
electrodes, leading to the enhancement of sensitivity.
40
 Another example of successfully 
applying nanomaterial into biosensing field is carbon nanotubes (CNTs) based bionsensors. 
Since the discovery in 1991, CNTs have attracted extensive interest due to their unique 
structural, mechanical, electrical and chemical properties. CNTs are able to mediate fast 
electron-transfer kinetics for numerous electroactive species, such as hydrogen peroxide
41
, 
NADH
42-43
, cytochrome c
44
, ascorbic acid
45
 etc. In addition, the large length-to-diameter ratios of 
CNTs provide high surface-to-volume ratios. Moreover, the results from cell culture of neural 
cells on carbon nanofiber (CNF) arrays (one type of CNTs) showed the great potential of such 
nanostructured materials as a 3D interface between the neural tissues and solid-state electronics 
due to their superior chemical, electrical and mechanical properties.
46
 Recently, Syed et al. 
discovered that electrochemical signal on VACNF nanoelectrode arrays (NEAs) can be greatly 
improved by using alternating current voltammetry (ACV) due to the unique conically stacked 
graphitic structure of CNFs which opened a new capacitive pathway for AC current.
47
 CNF 
NEAs with enhanced performance using ACV have later been successfully applied in the 
quantification of the activity of a cancer related protease, cathepsin B, in complex cell lysates.
1-2
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However, like any emerging field, application of nanomaterials for biosensing is facing 
many challenges. For example, mechanism of some interaction between biomolecules and 
nanomaterials still need to be clarified. Due to the special structures and functions that biological 
molecules possess, how to fully use them to fabricate single molecules multifunctional 
nanocomposites or nanoelectrode remains as a great challenge. How to enhance the sensitivity 
and specificity, and realize miniaturization and multiplexing are also challenging. Future work 
should focus on clarifying the mechanism of interaction between biomolecules and 
nanomaterials on the surface of electrodes, developing multiplexing system and looking for 
novel properties to fabricate new generations of biosensors. Nevertheless, nanomaterials-based 
biosensors have shown prospective properties and will find broader application in food analysis, 
clinical diagnosis and environmental monitoring in the near future.  
 1.3 Biosensors for protease detection 
 1.3.1 Significance  
Proteases are ubiquitous in living organisms and regulate a multitude of biological 
processes.
48-50
 In living systems, the unbalance of protease and their inhibitors leads to many 
diseases such as cancer. Throughout cancer progression, all five classes of protease are involved, 
which are serine (e.g. urokinase-type plasminogen activator, plasmin, chymase), cysteine (e.g. 
cathepsin B, L, S, K, Q; caspases; bleomycin hydrolase), aspartate (e.g. cathepsin D and E), 
threonine (e.g. proteasome) and matrix metalloproteases (e.g. gelatinases A and B, meprin).
49, 51
 
It is found that proteases are not only expressed by cancer cells, but also found in non-neoplastic 
neighboring cells which are enslaved to promote tumor growth and invasion.
52-53
 Numerous data 
have demonstrated the role of proteases in promoting tumor growth and progression (Figure 
1.2).
49, 52
 For example, increased expression and/or activities of cathepsin B was found to 
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associate with many types of cancers, such as breast
54
, colorectal
55
, gastric
56
, lung
57
 and 
prostate
58
 carcinomas. Trypsin, one of the well-known digestive serine protease, has been found 
to be involved in cancer development and facilitating cancer proliferation, invasion and 
metastasis.
59-60
 Proteases involvement in cancer suggests that they can be useful markers for 
identifying patients who are suffering from cancer. Thus, there is an urgent need for the 
development of effective biosensors for protease detection in early diagnosis and treatment 
monitoring of cancers. 
               
Figure 1.2 The tumor microenvironment (TME). TME comprises different stromal cells in 
addition to tumor cells. These include vascular or lymphatic endothelial cells, supporting 
pericytes, fibroblasts, and both innate and adaptive infiltrating immune cells. Moreover, TME 
contains non-cellular components, including extracellular matrixes, growth factors, proteases, 
protease inhibitors and other signaling molecules that play important roles in stromal reactions in 
TME.
52
 (Adapted with permission from ref. 52. Copyright © 2013 Ivyspring International 
Publisher. License link: http://creativecommons.org/licenses/by-nc-nd/4.0/legalcode) 
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 1.3.2 Traditional detection methods for proteases 
Traditional methods for protease detection include FL method
61-62
, EC method
1-2, 63-65
, 
SPR
66
, colorimetric assay
67
, ELISA
68
, reverse transcription (RT) PCR
69
 and high-performance 
liquid chromatography (HPLC)-MS
70
 etc. 
With the advance of studying proteolytic process by genomic and proteomic approaches, 
short peptide substrates for many kinds of proteases have been identified, thus facilitating rapid 
and facile methods to study the activities of the corresponding proteases.
62, 71-72
 By attaching 
peptide substrates with appropriate reporters, such as FL and bioluminescence, the proteolytic 
activity of the corresponding proteases can be studied.
73-74
 For example, highly selective 
fluorogenic substrate benzyloxycarbonyl-Arginine-Arginine-7-amino-4-methylcoumarin (Z-Arg-
Arg-AMC) has been used to study cathepsin B activity in a 96 well plate.
75
 The cleavage 
between arginine and AMC dye by cathepsin B results in the increase of the fluorescence which 
was recorded by a fluorescence microplate reader in kinetic mode. In this way, proteolytic 
activity of cathepsin B can be studied. Another common fluorescent method to assay the protease 
is based on fluorescence resonance energy transfer (FRET) where two fluorescent molecules are 
attached to each end of the substrate peptide with a distance less than 10 nm. The excited state 
donor molecule may transfer energy to an acceptor molecule through nonradiative dipole-dipole 
coupling.
76
 The efficiency of the energy transfer is inversely proportional to the sixth power of 
the distance between the donor and the acceptor.
77
 The energy transfer is disrupted by the 
cleavage of the peptide substrate by the protease, thus leading to the ratio change of the 
fluorescence from the donor and the acceptor, or the increase of the fluorescence if the acceptor 
is a quencher (Figure 1.3a).
62
 However, the energy transfer is often hindered by cross-talk 
between two fluorescent proteins with narrow Strokes shift and the process of genetically 
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engineered cell lines to express the fluorescence protein is very tedious.
62
 Compared to organic 
dyes and fluorescent proteins, quantum dots (QDs) have superior photophysical properties, such 
as broad absorption spectra with large molar extinction coefficients at wavelengths from the UV 
to the visible
78-80
, size-dependent emission band spanning from UV to infrared
81-82
, excellent 
photostability and high quantum yield
83-84
. In FRET system, fluorophore or quencher is used in 
conjunction with QDs (Figure 1.3b). Energy acceptor groups (fluorophore or quencher) were 
bound to the surface of the QD through a peptide sequence which leads to quenching of the QD 
emission via FRET. The cleavage of the peptide sequence due to protease activity results in the 
recovery of the QD fluorescence.
85-86
  
 
Figure 1.3 Schematic of FRET-based probe for the detection of protease activity. (a) 
Conventional FRET. (b) QD-based FRET. D and A indicate energy donor and energy acceptor.
62
 
(Adapted with permission from ref. 62. Copyright © 2012, Ivyspring International Publisher. 
License link: http://creativecommons.org/licenses/by-nc-nd/4.0/legalcode)  
Common EC methods to monitor protease activity include cyclic voltammetry (CV), 
electrochemical impedance spectroscopy (EIS), differential pulse voltammetry (DPV) and 
10 
amperometry. For CV, DPV and amperometry, the redox species-labeled peptide chain was often 
used. For example, the interaction between ferrocene (Fc)-labeled peptide on the gold electrode 
and proteolytic enzymes trypsin and α-thrombin was investigated by CV (figure 1.4).64 
Oxidation of the Fc head gave rise to a current passing through the electrode, which was used as 
a signal reporter for the labeled peptide. The protease activity can be detected by monitoring the 
loss of the Fc label due to the cleavage of the peptide chain by the proteolytic enzymes. EIS is 
another common EC method to study protease activity. It is used to characterize the electrode 
processes and complex interfaces by studying the system response to the application of a 
periodic small amplitude ac signal. Mahmoud et al. utilized EIS to trace the alteration of the 
interfacial properties of the electrode due to the interaction between HIV-1 protease and Fc-
pepstatin conjugate.
65
 The binding of HIV-1 protease to the Fc-pepstatin/carbon nanotube/gold 
nanoparticle modified electrode surface increased the film thickness, resulting in an increase of 
the resistance to charge transfer. Our group recently reported detection of cathepsin B proteolytic 
activity using Fc-labeled tetrapeptide by ACV on vertically aligned (VA) CNFs fabricated 
NEAs.
1-2
 This design enables the use of high AC frequencies (~1 kHz) with enhanced EC 
signals. The proteolysis of the Fc-tetrapeptide by cathepsin B produces decay in the ACV peak 
current versus the reaction time. The exponential component of the data can be quantitatively 
analyzed using a heterogeneous Michaelis-Menten model.
2
 Compared to the optical methods, EC 
approaches are much simple and avoid specific synthesis of FL labels and sophisticated 
instrumentations.  
11 
 
Figure 1.4 Schematic representation of the EC system for the detection of thrombin activity.
64
 
(Adapted with permission from ref. 64. Copyright © 2010, American Chemical Society.)  
Other than FL and EC methods, ELISA and RT-PCR are also commonly used approaches 
in molecular biology to detect proteases or their mRNA in the fluids. For ELISA, the basic 
immunology concept of an antigen binding to its specific antibody was used, which allows 
detection of small quantities of antigens such as proteins, antibody and peptides in the fluid.
87
 
Taking sandwich type ELISA as an example, the surface is bound with the capture antibody and 
the protease-containing sample is then added to generate protease binding to the capture 
antibody. After removing unbound protease, the detecting antibody is added, and binds to a 
different epitope of the protease. Following that, enzyme-linked secondary antibody is added and 
binds to the detecting antibody. Finally, the substrate is added, which is converted by the enzyme 
into a product with a specific color or fluorescent signal. The absorbance or fluorescence signal 
is measured to determine the quantity of the protease. However, the cross-reactivity might occur 
with the secondary antibody, leading to false positive results. For RT-PCR, it allows the 
detection and quantification of mRNA corresponding to the protease and is the most sensitive 
technique for RNA detection currently available. In RT-PCR, using a reverse transcriptase, the 
RNA template is first converted into a complementary DNA (cDNA) which is then used as a 
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template for exponential amplification using PCR. However, RT-PCR is only a semi-quantitative 
method for determining the mRNA levels of the proteases.
69
 In addition, both RT-PCR and 
ELISA are time-consuming and involve costly instruments. Beyond that, it is not possible to 
achieve real-time monitoring of protease activity with such methods. HPLC has also been used 
as a common chemical analysis method to study the proteolysis reactions, but is subjected to 
similar time and cost constraints.
70
  
 1.4 Biosensors for DNA detection 
DNA is a molecule that encodes the genetic information to instruct the development and 
function of all living organisms and many viruses.
88
 The nucleotide unit consists of nitrogen-
containing four different nucleobases (G-guanine, A-adenine, T-thymine or C-cytosine), 
deoxyribose and a phosphate group. The detection of DNA base sequence or DNA sequencing is 
critical for disease diagnosis (such as blood-borne pathogen detection), environmental testing for 
bacterial contamination, forensic analysis, genetic prognosis of disease progress and responses to 
drug treatment, etc.  
Techniques for DNA detection fall into two categories, PCR and DNA microarray. 
Depending on the type of output signal, different detection approaches have been used in DNA 
microarray technique, such as raman spectroscopy
33
, EC method
14
, SPR spectroscopy
34
, quartz 
crystal microbalance (QCM) technique, FL and colorimetric methods. A number of them are 
combined with GNPs and other nano-structured materials in order to amplify the signal and 
improve the sensitivity of DNA detection. 
PCR enables to produce millions of copies of a specific DNA sequence within hours for 
molecular and genetic analyses. Most mapping techniques in the Human Genome Project (HGP) 
relied on PCR. PCR can be applied in DNA fingerprinting/profiling and detection of bacteria or 
13 
viruses. General procedure of PCR can be divided into three steps. First, double-stranded DNA is 
separated at temperatures above 90 °C. Second, oligonucleotide primers are annealed at 50-60 
°C. Finally, optimal primer extension occurs at 70-78 °C under the catalysis by DNA 
polymerases. Once an adequate amount of DNA has been produced with PCR, the sequence of 
nucleotide pairs in the DNA can be determined by using various biomolecular sequencing 
methods such as enzymic polymerization
89-90
, chemical methods based on DNA degradation
91-92
, 
the Pyrosequencing method
93-95
 (DNA sequencing in real time by the detection of released 
pyrophosphate) and single molecule sequencing with exonuclease
96-97
. Real-time PCR, in which 
amplified DNA is detected as the reaction progresses in real time, has become more and more 
popular compared to conventional PCR due to its high speed, high sensitivity, good 
reproducibility and minimal carryover contamination leading to false-positives.
98
  
            
Figure 1.5 Schematic illustration of DNA microarray technology based on FL method. 
(Courtesy: National Human Genome Research Institute. http://www.genome.gov/10000533) 
14 
DNA detection can also be achieved by using DNA microarray technique. Thousands of 
spotted samples, such as DNA, cDNA and oligonucleotides, are arrayed in orderly rows and 
columns on a solid support (usually a microscope glass slide). This allows determining thousands 
of complementary binding of unknown DNA sequences at once. There are many ways to realize 
the event of complementary binding. The most common way is to rely on FL method, in which 
unknown DNA sequences are labeled with FL dye (Figure 1.5). As shown in figure 1.5, When 
co-hybridizing tumor samples (red dye) and normal sample (green dye), they will compete for 
the spotted synthetic DNAs on the microarray slide. If the spot is red, this means that the specific 
gene is more expressed in tumor than in normal. The spot is green which means the gene is more 
expressed in the normal tissue. If the spot is yellow, that means the gene is equally expressed in 
both normal and tumor tissue. 
 Raman spectroscopy is another method to detect DNA. Raman spectroscopy provides 
the information of molecular vibration that is used to identify and quantify the sample. This 
technique involves shining a monochromatic light source such as laser on the sample and 
detecting the scattered light. The light interacts with molecular vibrations in the system, resulting 
in the shift of the photon energy. The shift gives information about the vibration mode of the 
system. For example, Cao et al. reported multiplexed detection of oligonucleotide targets by 
GNP probe labeled with oligonucleotides and Raman-active dyes, Cy3.
33
 A chip was spotted 
with 15-nucleotide capture strands which hybridized with 30-nucleotide target sequence. The 
chip was then treated with nanoparticle probes to hybridize with the overhanging region of the 
target sequence (Figure 1.6). Finally, the chip was treated with a Ag enhancement solution and 
studied by a Raman spectrometer. The Ag particles grew around the Cy3-labeled nanoparticle 
probes, resulting in large Ramen scattering enhancements. The Raman scattering signals are 
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caused exclusively by the Cy3 dye molecules immobilized on the particles and the scattering 
frequency for each Raman line remains constant. The reliable surface-enhanced Raman 
scattering (SERS) signals from the Cy3-labeled nanoparticle probes allow using the Raman 
spectrum of Cy3 as a spectroscopic fingerprint to detect the target oligonucleotide strand. It was 
claimed that the detection limit of this method was 20 femtomolar. Compared to the traditional 
FL detection method, this nanoparticle-based Raman technology has several advantages, such as 
more selection of non-overlapping probes, higher multiplexing capabilities and higher 
sensitivities due to GNPs labeling.  
                                 
Figure 1.6 The schematic of a three-component sandwich assay for DNA detection using SERS 
spectroscopy.
33
 (Adapted with permission from ref. 33. Copyright © 2002, the American 
Association for the Advancement of Science.)  
EC methods have received considerable attention in recent years in the development of 
DNA biosensors due to their high sensitivity, low cost, ease to be developed as portable system 
and on-site monitoring.
99-102
 The strategies of EC signaling are based on the oxidation of DNA 
bases, the redox reactions of reporter molecules on the electrode surface by specific DNA probe-
target interactions and by charge transport reactions mediated by π-stacked base pairs. The 
16 
earliest EC DNA detection was based on the oxidation and reduction of DNA at a hanging 
mercury drop electrode.
103
 The amount of DNA can be simply reflected by the amount of DNA 
reduced or oxidized. The methods to oxidize target DNA indirectly have also been explored. 
Polypyridyl complexes of Ru(II) or Os(II) to mediate the EC oxidation of guanine is often used. 
For example, Li et al. reported ultrasensitive DNA detection based on VACNF NEAs using CV 
and ACV.
104
 Oligonucleotide probes were selectively functionalized to the open edges of the 
nanotubes. Since small guanine oxidation peak cannot be resolved by CV measurement due to 
the high background at potentials above +0.90V, Ru(bpy)3
2+
 was used to provide amplified 
signal for DNA detection (figure 1.7). A detection limit of subattomole oligonucleotide targets 
was achieved by this EC system. EC method has been proven to be a fast, cheap and simple 
solution for molecular diagnosis, particularly for point-of-care and field application. 
                      
Figure 1.7 The schematic mechanism of Ru(bpy)3
2+
 mediated guanine oxidation on the DNA 
attached electrode surface.
104
 (Adapted with permission from ref. 104. Copyright © 2003, 
American Chemical Society.) 
SPR technique has been also applied in DNA microarray detection. SPR is an optical 
technique that measures the changes in the refractive index of the medium near a noble metal 
surface (within 200 nm).
105-107
 The typical sensing surface is a thin film of gold deposited on a 
glass substrate that forms the floor of a small volume flow cell where an aqueous solution is 
17 
passed. The receptor molecule is usually immobilized on the sensing surface and the analytes are 
injected into the aqueous solution through the flow cell. Monochromatic, p-polarized light is 
reflected from the back of the glass-gold interface. The reflected light beam is monitored as the 
reaction occurs at the interface of gold film and solution.
34
 Thus, SPR is a highly sensitive 
method for label-free detection of the interactions of biomolecules. By coating the SPR sensing 
surface with probe DNA, this technique can be used for the study of affinity binding and 
detection of DNA target in the sample solution. For example, Kick et al. deposited thiol-
modified signal-stranded probe DNA on the gold surface of the microchip and investigated the 
effect of different parameters on hybridization by means of SPR spectroscopy. A detection limit 
of 0.5 ng/μL (2.6 nM) was achieved in this study.108 However, SPR spectroscopy has its own 
disadvantages. For instance, SPR cannot easily discriminate between the specific and non-
specific interactions on the sensor surface.
109
  Elaborate washing process is not able to remove 
the non-specifically bound materials from the surface completely. In addition, SPR is not 
sensitive enough to detect low molecular weight compounds since it is mass sensitive. Limited 
sensor area is another challenge in SPR application too.  
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Chapter 2 - Fabrication and Characterization of Vertically Aligned 
Carbon Nanofiber Nanoelectrode Array (VACNF NEAs) 
 2.1 Introduction 
CNFs are cylindrical nanostructures having diameters varying from a few to hundreds of 
nanometers and lengths in the order of micrometers.
110-111
 Depending on the stacking 
arrangement of graphene sheets in the structure, the shape of CNFs can be classified as platelet, 
ribbon-like and herringbone.
112
 The mechanical strength and electric properties of CNFs are 
similar to CNTs which are allotropes of carbon with a cylindrical nanostructure.
113
 The primary 
distinguishing characteristic of CNFs from CNTs is that their whole surface area can be activated 
due to the free edge sites on the outer wall of CNFs.
114
 CNFs can be activated by nitric acid or 
EC oxidation without degradation of their backbones structural integrity. The oxygen-containing 
activated sites are ideal for the immobilization and stabilization of biomaterials, an application 
that can be utilized for the development of biosensors. At the same time, they can transmit EC 
signals acting as transducers due to their good electrical conductivity.
115
 Vertically aligned 
structures are typically referred to the structures that are orientated perpendicular to the substrate 
where they are grown. For a nanofiber, this means that the structure is straight and its axis is 
normal to the substrate.
110
 VACNFs can be prepared as a dense mat or individual freestanding 
structures (sometimes arranged into a regular array). Van der Waals interaction between CNFs 
usually generates vertical alignment in a very dense format while an electric field is often 
required in order to form isolated freestanding CNFs.
116
 Here, I briefly introduce synthesis of 
VACNFs by plasma enhanced chemical vapor deposition (PECVD) method followed by silicon 
dioxide (SiO2) encapsulation and reactive ion etching (RIE) to produce VACNF NEAs for 
biosensor applications.     
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 2.2 Fabrication of VACNF NEAs 
Fabrication of CNF NEAs for biosensor application generally involves (1) contact metal 
and catalyst metal deposition; (2) growth of VACNFs by PECVD; (3) SiO2 encapsulation and (4) 
mechanical polishing and RIE etching to expose the tips of the SiO2 embedded VACNFs. The 
experimental procedures were detailed in the following sections.  
 2.2.1 Contact metal and catalyst deposition 
Contact metal Cr and catalyst Ni were sputtered on the 1 cm x 2 cm SiO2 substrate which 
was sonicated in isopropanol for 10 to 30 min and dried overnight in 100 °C oven. The 
thicknesses for Cr layer and Ni layer were 100 nm and 20 nm, respectively. An ion beam 
sputtering coater (Model 681, Gatan, Pleasanton, CA, USA) was used with 10.0 keV beam 
energy. During ion sputtering, the substrate in the coater chamber was rotated at the speed of 35 
rpm, titling angel of 5° and rocking rate of 12 °/s. The coating rate for Cr is about 1.2 Å/s and for 
Ni is about 0.7 Å/s.  
 2.2.2 Plasma enhanced chemical vapor deposition (PECVD) for VACNF growth 
Brush-like VACNFs were grown on the metal deposited SiO2 substrate by using a 
PECVD system (Black Magic, Aixtron, Swavesey ,Cambridge, UK). First, the sample was 
placed on the cathode plate in the PECVD chamber. Then, the sample was annealed at 500 °C 
for 60s under the vacuum with a base pressure of ~0.11 mbar. Acetylene and ammonia were then 
introduced into the chamber at flow rates of 63 and 250 sccm, respectively and with 5.48 mbar 
processing pressure. At the same time, the temperature of the cathode plate was ramped up to 
750 °C while the DC plasma was started (520 V and 45 W). Under above conditions, a 20 min 
deposition generated a VACNF arrays with fiber diameter of 50 to 100 nm and length of ~5 μm 
on the SiO2 substrate.  
20 
 2.2.3 Silicon dioxide (SiO2) encapsulation 
As-grown CNF arrays were embedded in SiO2 insulating layer in order to obtain 
mechanical stability and avoid electrochemical background from the underlying metal film and 
sidewall of CNFs. A home built CVD system with a tube furnace (Thermo Electron Corporation, 
Asheville, NC, USA) was used for this purpose. After the base pressure of CVD chamber 
declined to ~50 mTorr, the chamber with as-grown CNF chip was heated up to 730 °C. 
Tetraethyl orthosilicate (TEOS) was then introduced into the chamber and deposited between 
each individual CNF at a vapor pressure of ~350 mTorr for 4 hr and ~400 mTorr for 3 hr. After 7 
hr deposition, the VACNF arrays were fully embedded in the SiO2 layers.  
 2.2.4 Planarization and reactive ion etching (RIE) 
Since the surface of SiO2 layer covering the top of the VACNF arrays was rough and 
uneven, mechanical polishing was applied using 0.3 μm alumina slurry to produce a flat surface. 
RIE with a mixture of CHF3 and O2 gases was then performed with NRE-3000 (Nano-Master 
Inc., Austin, TX) to selectively etch away desired amount of SiO2. It can be controlled to expose 
20% to 60% of the CNF tips based on the length variation of CNFs. A typical VACNF NEA in 
this study consists of randomly distributed CNF tips with an average CNF diameter of ~100–200 
nm and an average spacing over ~1 µm (corresponding to a density of ~(1–10) x 107 CNFs-cm-
2
).   
 2.3 General experimental details for protease detection 
 2.3.1 Materials 
3-Aminopropyl-triethoxysilane (APTES), 2-(2-methoxyethoxy)ethoxyacetic acid, 1-
ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC), 1-hydroxy-2,5-
dioxopyrrolidine-3-sulfonic acid sodium salt (sulfo-NHS), sodium hydroxides, and 6-amino-1-
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hexanol were purchased from Sigma-Aldrich (Saint Louis, MO, USA). 2-(4-Morpholino)ethane 
sulfonic acid (MES) and dithiothreitol (DTT) were purchased from Thermo Fisher Scientific 
(Fair Lawn, NJ, USA). Recombinant human legumain/asparaginyl endopeptidase (molecular 
weight of 49 kDa) and recombinant human cathepsin B (molecular weight of 29 kDa) were 
acquired from R&D Systems Inc. (Minneapolis, MN, USA). Only a few control experiments in 
immunoprecipitation study used cathepsin B purchased from Santa Cruz Biotechnology Inc. 
(Dallas, TX, USA). Before use for enzymatic reactions, legumain was activated in an activation 
buffer, consisting of 50 mM CH3COONa (pH 4.0, adjusted by adding acetic acid) and 100 mM 
NaCl. Cathepsin B was activated in an activation buffer of 5 mM DTT and 25 mM MES (pH 
5.0). Substrates Z-Ala-Ala-Asn-AMC and Z-Leu-Arg-AMC for fluorescence assay were 
obtained from Bachem (Torrance, CA, USA). Human breast whole tissue lysate (adult normal) 
with the stock concentration of 4.9 mg·mL
-1
 was purchased from Novus (Littleton, CO, USA). 
All aqueous solutions were prepared using 18.2 MΩ-cm resistivity deionized (DI) water from a 
bench-top water purifier (Barnstead EASYpure II RF/UV, Model D7035, Thermo Scientific, 
Asheville, NC, USA). For the details of synthesis of ferrocene-appended tetrapeptide for 
legumain cleavage (i.e. H2N-(CH2)4-CO-Ala-Ala-Asn-Leu-NH-CH2-Fc) and for cathepsin B 
cleavage (i.e. H2N-(CH2)4-CO-Leu-Arg-Phe-Gly-NH-CH2-Fc), please refer to Allan Prior’s 
Ph.D. dissertation 2014 and reference1.  
 2.3.2 Electrode functionalization toward protease detection 
To reduce nonspecific adsorption, the SiO2 surface of the VACNF NEAs was first 
passivated with protective moieties containing ethylene glycol. The chip was immersed in an 8 g 
L
-1
 solution of APTES in ethanol for 20 minutes to produce a primary amine derivatized surface. 
The chip was treated with 50 µL solution of 0.1 mM of 2-(2-methoxyethoxy)ethoxyacetic acid, 
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100 g L
-1
 of EDC and 50 g L
-1
 of sulfo-NHS, and incubated at room temperature for 2 hours in 
an enclosed chamber (Arrayit, CA, USA). The carboxylic acid group of 2-(2-
methoxyethoxy)ethoxyacetic acid formed an amide bond with the amino function on the chip 
surface, leaving ethylene glycol moiety covering the surface. The molecules attached to the CNF 
tips were then removed by electrochemical etching at 1.2 V (vs. Ag/AgCl (3 M KCl)) for 20 
seconds in 1.0 M NaOH solution. This process regenerated clean CNF tips which contain 
abundant carboxylic acid functional groups.  
The tetrapeptide H2N-(CH2)4-CO-Ala-Ala-Asn-Leu-NHCH2-Fc for legumain study or 
H2N-(CH2)4-CO-Leu-Arg-Phe-Gly-NH-CH2-Fc for cathepsin B study was covalently linked to 
the VACNF NEA by forming amide bond facilitated by EDC and sulfo-NHS. Typically, a 
solution of 10 μL of 10 mM tetrapeptide mixed with 90 μL of 10 g L-1 EDC and sulfo-NHS was 
applied onto the electrochemically activated VACNF NEA chip and incubated in the enclosed 
Arrayit chamber at room temperature for 2 hours. Control experiments and HPLC-MS 
characterization confirmed that only the end –NH2 group of the tetrapeptide formed amide bond 
with the carboxylic acid group on the VACNF NEA. The –NH2 and NH functions in asparagine 
and arginine moieties in the peptide do not react with the carboxylic acid group under the 
reaction conditions. In order to stabilize the electronic signal, the CNF electrode surface was 
further dipped into a solution of 5 mL of 1 mM 6-amino-1-hexanol containing 5 g L
-1
 EDC and 2 
g L
-1
 sulfo-NHS so that the unreacted –COOH sites were linked with 6-aminohexanol. 
 2.3.3 Electrochemical measurements 
The EC measurements were performed in a TEFLON cell with a total volume of 250 µL. 
The cell was sealed against a VACNF NEA chip with a 3-mm i.d. O-ring in a three-electrode 
configuration with the VACNF NEA as the working electrode, an Ag/AgCl (3M KCl) reference 
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electrode and a coiled Pt wire as the counter electrode. The electrolyte solutions consisted of 50 
mM MES (pH = 5.0) and 250 mM NaCl for legumain experiment and 25 mM MES (pH = 5.0) 
for cathepsin B experiment. The average AC current was measured by applying an AC voltage 
bias on the DC staircase waveform with the potential sweeping from -0.05 to +0.65 V for 
legumain experiment and -0.1 V to +0.75 V for cathepsin B experiment, both at 10 mV·s
-1
 scan 
rate. The parameters including AC voltage amplitude and frequency were varied in specific 
experiments and specified as the results are presented in later sections. 
 2.4 Characterization of VACNF NEAs 
Characterization of non-patterned VACNF NEAs by SEM and CV 
 
Figure 2.1 (a) SEM image of freestanding as-grown VACNFs (45° view) after PECVD. Scale 
bar: 4 µm (Insert: scale bar ‒ 500 nm) (b) SEM image (top-down view) of CNFs after being 
encapsulated with SiO2 using TEOS-CVD. Scale bar: 3 µm. (Insert: 45° view. Scale bar: 500 
nm.). (c) CV of as-grown SiO2 insulated vertically aligned CNF. The measurement was done in 
50 mM K3Fe(CN)6 and 1.0 M KCl electrolyte at a scan rate of 50 mV·s
-1
. 
As-grown VACNFs on the Si substrate after PECVD is shown in Figure 2.1a. Typically, 
it consists of randomly distributed CNF tips with an average CNF diameter of ~100–200 nm and 
an average spacing over ~1 µm (corresponding to a density of ~(1–10) x 107 CNFs-cm-2). Figure 
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2.1b shows the CNFs are embedded in SiO2 insulating layer with selective tips exposed by 
chemical mechanical polishing and RIE. The length of exposed CNF tips was controlled at ~50–
300 nm by varying the RIE time to selectively remove SiO2.  
CV with 50 mM K3Fe(CN)6 and 1.0 M KCl has been used for characterization of 
electrodes. Due to the length of the diffusion layer is smaller than the average separation between 
the neighboring CNF, the CV curve is thus presented as a sigmoidal shape (Figure 2.1c), 
indicating the presence of a steady-state diffusion-limited current at each CNF.
117
 The VACNF 
NEAs with low density is favorable for biosensor application. The CV signal is defined as the 
height of the sigmoidal curve (i.e. the steady state or limiting current il) which is given by 
Equation 2.1 for an ideal inlaid disc electrode
118
:  
                                            𝑖𝑙 = 4𝑛𝐹𝐶0
∗𝐷0𝑟                                                                   (2.1) 
where n is the number of electrons transferred, C0* is the bulk concentration of the species 
(mol/cm
3
), D0 is the diffusion coefficient (cm
2
/s), r is the electrode radius (cm) and F is the 
Faraday constant (96485 s·A/mol). Different with macro-electrode such as macro glassy carbon 
electrode (GCE) where the current signal is proportional to the square root of the scan rate, the 
limiting current of NEAs is independent with the scan rate.  
Characterization of patterned VACNF NEAs by SEM and CV 
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Figure 2.2 (a) Bright field microscope images of patterned VACNF NEAs using a 4x objective 
lens. (b) SEM image at 45° perspective view of the pattern VACNF NEAs. (c) CV of the 
patterned VACNF NEAs on each single microelectrode pads. (d) CV of patterned VACNF 
NEAs with all nine microelectrode pads connected together. The measurements were done in 50 
mM K3Fe(CN)6 and 1.0 M KCl electrolyte at a scan rate of 50 mV·s
-1
. 
Regular patterned VACNF NEAs can be mass-produced as multiplex chips on 
independently addressed microelectrode pads using UV- and e-beam lithography.
119
 Figure 2.2a 
shows nine 200 µm x 200 µm microelectrode pads of ~100 nm-thick Cr film in a 3 x 3 array on a 
SiO2-covered Si wafer. VACNFs were grown in regular 1 m x 1 m lattice on these 
microelectrode pads to form embedded NEAs which were independently connected with the 
external contact pads (1 mm x 1 mm) through the metallic line underneath the SiO2 layer. Figure 
2.2b shows the zoom-in image of exposed VACNF tips of ~100 nm in diameter protruding over 
the SiO2 matrix. Figure 2.2c and 2.2d show the CVs of a 50 mM K3Fe(CN)6 solution from all 
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nine VACNF NEAs separately and together. Clearly, they all showed the characteristic 
sigmoidal shape with low background and almost identical limiting current, indicating the high 
uniformity of these NEAs. 
 2.5 Conclusions 
In summary, the procedure of the fabrication of as-grown VACNF NEAs has been 
discussed. The electric field of PECVD could help to produce vertically aligned carbon structure. 
By selectively etching away the SiO2 insulating layer and exposing the tips of the VACNFs by 
RIE, VACNF NEAs can be fabricated and used as a biosensor through functionalizing the tips 
with biological molecules, such as peptides
1-2
 and DNA
104
. VACNF NEAs have sigmoidal 
shaped CV curve due to the length of diffusion layer is much smaller than the separation between 
the adjacent fibers. Finally, low background sigmoidal shaped CV curve and almost identical 
limiting current indicated the high uniformity of the e-beam patterned VACNF NEAs.  
  
27 
Chapter 3 - Cancer-related Protease Biosensor Based on Enhanced 
AC Voltammetry Using VACNF NEAs 
Reproduced in part by permission of American Chemical Society. 
Published as: Swisher, L. Z.; Syed, L. U.; Prior, A. M.; Madiyar, F. R.; Carlson, K. R.; 
Nguyen, T. A.; Hua, D. H.; Li, J. J. Phys. Chem. C 2013, 117, 4268-4277.  
 3.1 Introduction 
Proteases, the proteolytic processing proteins, are ubiquitous in living organisms and 
regulate a multitude of cellular processes including the cell cycle, hormone activation, apoptosis 
and angiogenesis.
48-50
 The cysteine protease legumain, also known as asparaginyl endopeptidase 
(AEP), has a strict specificity for hydrolysis of asparaginyl bonds.
120
 It is highly expressed in 
macrophages, on the cell surfaces and membranous vesicles in the metastatic and invasive solid 
tumors where it activates other proteases such as cathepsin B, H and L, that have both 
elastinolytic and collagenolytic activities.
121-123
 However, overexpression of those cysteine 
proteases was not found in the normal tissue. In breast cancer, several recent studies have shown 
that absence of the cysteine protease inhibitor leads to increased growth and metastasis.
124
 Thus, 
rapid detection of the presence and activity of cancer-mediated proteases (i.e. legumain and 
cathepsin B), should be developed for enhancement of treatment.
125
 
Traditional methods for enzyme activity study include gel electrophoresis, HPLC, ELISA 
and optical methods.
126-129
 These methods require specific synthesis of peptides, fluorescent 
labels and sophisticated instrumentations, which are high-cost and time-consuming. 
Radioimmunoassay (RIA) had been widely used as an highly sensitive detection method but is 
diminished nowadays due to health safety and environment concerns.
130
 Simple rapid electronic 
and/or electrochemical methods to detect enzyme activities are thus important in developing 
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portable systems for point-of-care diagnosis and treatment monitoring of diseases such as 
cancers. Recently, EC methods using CV measurements of redox-labeled peptides attached on 
macroscopic gold electrodes have been demonstrated in detecting high-activity proteases such as 
trypsin, thrombin and plasmin.
64, 131
 Due to the localized sensing mechanism, an array of 
electrodes functionalized with different peptides could potentially detect multiple enzymes in a 
small sample volume. However, electrochemical detection of proteases that are more relevant to 
cancers, such as legumain and cathepsin B, has not been reported. These enzymes have much 
lower catalytic activity, making the measurement more difficult.  Here we focus on a new 
electrochemical technique enabled by nanostructured electrodes that can successfully detect 
these enzymes. 
It is well known that reducing the electrode size can dramatically enhance the detection 
sensitivity and temporal resolution of electrochemical measurements.
132-133
 This trend extends 
from the scale of microns to nanometers. Well-separated NEAs, either in regular pattern or in 
random distributions (also referred to as nanoelectrode ensembles (NEEs)), have attracted 
extensive interests for highly sensitive electroanalysis, measuring fast electrochemical kinetics, 
and biosensing.
134-136
 Fabrication methods such as nanosphere lithography and E-beam 
lithography have been developed for the well-ordered NEAs.
137-138
 Carbon based NEAs are 
particularly attractive for biosensors due to the wider applicable potential window and ease in 
biofunctionalization through robust covalent attachment. Development in this area, however, has 
been limited by the lack of readily available methods to fabricate reliable NEAs. Recent research 
in carbon nanotechnology has provided a method to fabricate well-controlled NEAs using 
VACNFs embedded in insulating materials.
136, 139-140
 Both precisely patterned and randomly 
distributed CNFs with the average diameter of 50–200 nm and uniform vertical alignment have 
29 
been fabricated on 4” Si wafers141 and can be mass-produced into robust NEAs on individually 
addressed microelectrodes forming an “array-in-array” format. Various applications of VACNF 
NEAs with and without further encapsulation of insulating materials have been demonstrated for 
various biosensing or biomedical applications, including DNA hybridization analysis,
104
 glucose 
detection,
139
 electrochemical sensing of neurotransmitters,
142
 neural electrical recording,
143
 and 
gene delivery.
144
 Here we employ the embedded VACNF NEAs for enzymatic studies. The SiO2 
matrix was selectively etched by plasma etching to expose ~50–200 nm long CNF tips over the 
surface (as shown in Figure A.1). Specific peptide substrates were functionalized at the exposed 
CNF tips and subjected to proteolysis by proteases. The small radius of the CNF tips (~50–100 
nm) protruding over the SiO2 matrix makes it easier for enzymes to access to the peptides,  
avoiding the steric hindrance that is normally encountered on macroscopic surfaces. 
Generally, CV measurements of bulk redox species using embedded VACNF NEAs 
show characteristic sigmoidal curves,
104, 145
 in which the tiny CNF tips carry much higher current 
densities than macro- or micro-electrodes. This feature indicates one of the predicted benefits of 
nanoelectrodes due to the nonlinear radial diffusion of redox species to the electrode surface.
146
 
The NEA also presents much smaller electrochemical cell time constant which allows the 
electrochemical measurement to be carried out at a much higher speed. These properties make 
NEAs attractive for rapid high-sensitivity biosensing applications.  
Recently, we discovered that the electrochemical measurements on VACNF NEAs can be 
significantly improved by applying an AC voltage bias on the direct current (DC) ramps in the 
common CV measurement, i.e. by using ACV.
47
 An anomalously high electron transfer rate was 
obtained with redox-active Fc molecules attached to the exposed CNF tips of the embedded 
NEAs.
47
 This was attributed to the unique conically stacked graphitic structure of the CNFs, 
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which opened a new capacitive pathway for AC current. As a result, ACV on VACNF NEAs can 
be carried out at much higher AC frequency (at kHz) than <100 Hz on macroscopic GCEs. Since 
the magnitude of the signal in ACV, i.e. AC current amplitude, increases monotonically with the 
AC frequency at < 1 kHz, the detection sensitivity can be greatly enhanced using VACNF NEAs. 
The ACV is particularly advantageous over common CV for measuring small quantities of 
surface-attached redox molecules since the electrons can be shuffled back and forth for many 
times between the electrode and each adsorbed molecules. Here, we report the application of this 
property on detection of the enzymatic activities of legumain and cathepsin B by monitoring the 
kinetic decrease of the ACV signals of Fc attached to the CNF tip through a specific peptide 
linker during proteolysis. The data are well explained with the Michaelis-Menten heterogeneous 
enzymatic model. 
 3.2 Design and electrochemical characterization of VACNF NEAs for 
protease detection 
Figure 3.1 shows the structure of an embedded VACNF NEA covalently attached with 
Fc-linked peptides at the exposed CNF tips. The Fc moiety at the distal end provides a reliable 
redox signal at ~0.25 V vs. Ag/AgCl (3M KCl) in ACV measurements. Upon supplied with the 
specific protease, the peptide is expected to be cleaved at the particular site. As a result, the Fc 
moiety is released from the electrode surface into the bulk solution, causing the redox signal to 
decrease. The kinetic of the enzymatic reaction at the electrode surface will be monitored by 
continuously repeated ACV measurements. The advantage of this method is that the appended Fc 
moiety provides a characteristic faradaic signal which can be easily separated from the unstable 
nonfaradaic background and other interfering redox signals. The key for this method is that the 
Fc signal needs to be relatively large and stable over the period of the kinetic measurements (up 
31 
to ~1 hour) and the ACV measurement at each point is fast enough to provide ~1 minute (or less) 
of temporal resolution. This may become challenging for enzymes requiring long peptide 
substrate sequences for specific recognition. The Fc signal involves electron transfer between Fc 
molecule and the electrode surface, which is highly sensitive to the Fc-surface distance and the 
molecular packing of the peptides on the electrode surface. Thus the electrochemical properties 
of Fc-linked peptide attached on VACNF NEAs need to be carefully characterized. 
 
Figure 3.1 Schematic diagram of the cleavage of Fc-linked tetrapeptides at the VACNF NEA tip 
by specific proteases. (a) A random VACNF array embedded in the SiO2 matrix. (b) Electron 
transfer from appended ferrocene at the distal end of the peptide to the underlying metal film 
electrode through the VACNFs and the loss of the electrochemical signal from ferrocene due to 
the cleavage of the peptide at specific sites.  
Figure 3.2 shows the comparison of ACVs of a macro-GCE and a VACNF NEA, both 
functionalized with the tetrapeptide H2N-(CH2)4-CO-Ala-Ala-Asn-Leu-NHCH2-Fc to be used for 
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legumain study. A peak current was observed at ~0.2 V vs. Ag/AgCl (3M KCl) for both 
electrodes. The amplitude of the peak current density (ip) in the ACVs with macro-GCE 
increased from ~1.0 x 10
-7
 A·mm
-2
 at 10 Hz to ~2.0 x 10
-7
 A·mm
-2
 at 40 Hz, but then dropped to 
zero at 1500 Hz. At the meantime, the background signal steadily increased from ~4.7 x 10
-7
, to 
1.8 x 10
-6
 and 2.8 x 10
-6
 A·mm
-2
, respectively. In contrast, although the ip of ACV with VACNF 
NEAs was not measurable at 10 Hz and 40 Hz, it rose clearly above the background at 1500 Hz, 
giving ~2.0 x 10
-8
 A·mm
-2
. Obviously, VACNF NEAs allowed the Fc signal to be detected at 
much higher frequency. It is noteworthy that the current density in Figure 3.2 was calculated 
with the geometric electrode surface area. As shown in Figure A.1, the actual exposed CNF 
surface area in the VACNF NEA is more than ~100 times less than the geometric surface area. 
Hence the real current density at the CNF tip is at least 10 times higher than that at the GCE. 
Generally, the electrochemical signal is very sensitive to Fc-surface distance since the electron 
transfer rate decays exponentially versus the Fc-surface distance. Hence electrochemical sensors 
based on redox reactions normally use linker molecules less than 2 nm in length. Here, the 
electron transfer on both GCEs and VACNF NEAs was not significantly affected by the 
tetrapeptide and the linker (with a fully extended length of ~2.5 nm). Experiments with an even 
longer octapeptide (Figure A.15) did not show notable difference in Fc signal, suggesting that the 
molecule might be folded back to the CNF surface.  
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Figure 3.2 Comparison of ACVs measured at 10, 40 and 1500 Hz of H2N-(CH2)4-CO-Ala-Ala-
Asn-Leu-NHCH2-Fc immobilized on a macro-GCE (a–c) and on a VACNF NEA (d–f). All the 
measurements were done in 500 µL of 50 mM MES (pH 5.0) and 250 mM NaCl. Sinusoidal 
waves with the fixed amplitude of 25 mV were superimposed on a DC staircase ramp from -0.05 
to +0.65 V at a scan rate of 10 mV·s
-1
. The measured average AC current at each point was 
normalized by the 7.1 mm
2
 geometric surface area defined by the 3-mm i.d. O-ring. The actual 
CNF surface area is ~100 times less. 
ACV uses a sinusoidal AC voltage superimposed on a DC potential ramp for 
voltammetric measurements. It has advantages over commonly used DC-based CV, particularly 
for biosensors, due to the ability to amplify the electrochemical signal of small quantity of redox 
tags by shuffling the electron between the redox tag and the electrode many times. In general, the 
signal increases with AC frequency at low frequencies but is saturated and then decreases at 
higher frequencies. In our previous study using VACNF NEAs, the optimum frequency for Fc 
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through a short NH2CH2- linker was found to be 40 times higher than that on the macro-GCE.
47
 
Figure 3.3 illustrates the similar phenomena with Fc attached to the electrode surface through the 
tetrapeptide and a longer linker group versus the AC frequency. Clearly, the optimum frequency 
which gave the maximum ip was 40 Hz for the GCE, but 1750 Hz for the VACNF NEA. Despite 
that both frequency values are about half of those with short NH2CH2- linker, the drastic 
difference between VACNF NEA and macro-GCE remained the same, i.e. the optimum 
frequency on the VACNF NEA was ~40 times of that on the GCE. The higher applicable AC 
frequency at VACNF NEA afforded a larger ACV signal (i.e. ip) and faster ACV measurements. 
Each ACV measurement in Figure 3.2 can be done in ~60–70 s. As a result, the kinetics of 
enzymatic cleavage can be monitored with continuously repeated ACV measurements at a 
temporal resolution of ~1 minute.  
 
Figure 3.3 (a) Background-corrected ACV peak current density ip,acv (normalized to the 7.1 mm
2
 
geometric electrode area) of  H2N-(CH2)4-CO-Ala-Ala-Asn-Leu-NHCH2-Fc immobilized on a 
GCE (square) and a VACNF NEA (filled circle) plotted against the AC frequency. (b) Plot of 
ip,acv versus logarithm of the AC frequency. Note: The real CNF surface area is ~100 times less 
than the geometric surface area defined by the O-ring. 
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The AC peak current density ip,acv can be extracted by subtracting the background (as a 
simple sloped straight line). These values are plot in Figure 3.3a versus the AC frequency. 
Clearly, the AC peak current density of the GCE shows a sharp peak with the maximum at 40 Hz 
and a full width at half maximum (FWHM) of ~140 Hz. The current value approximately 
increases linearly with the AC frequency but drops rapidly as the AC frequency exceeds 40 Hz. 
In contrast, the maximum AC peak current density was observed at 1750 Hz on the VACNF 
NEA and the FWHM asymmetrically spread over 5000 Hz, indicating a large range of frequency 
that can be used. The current density increases about linearly with the frequency up to ~1000 Hz. 
When the peak current density is plot versus the logarithm of the AC frequency as shown in 
Figure 3.3b, the curves obtained with the GCE and the VACNF NEA show similar shape but 
with shifted peak frequency. It needs to be noted that the ACV measurements are not stable with 
the GCE. The peak shape changed significantly in about 10 minutes as shown in Figure A.2, 
which limits the use of GCEs for the measurement of enzymatic kinetics. In contrast, the peak 
shape of the ACV curve of VACNF NEAs is much more stable. 
 
Figure 3.4 Background-corrected ACV peak current density ip,acv (normalized to the 7.1 mm
2
 
geometric electrode area) of  H2N-(CH2)4-CO-Ala-Ala-Asn-Leu-NHCH2-Fc immobilized on a 
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GCE and a VACNF NEA plotted against the amplitude of the AC voltage (square: GCE, filled 
circle: VACNF NEA).  
The peak current in ACVs also depended on the amplitude of the applied AC voltage. 
Figure 3.4 shows that there is a small difference between the GCE and the VACNF NEA. The 
peak current density (ip,acv) reached to the highest value of ~1.5 x 10
-6
 A·mm
-2
 at the amplitude 
of 0.35 V for GCE while the peak current density kept increasing at the amplitude up to 0.50 V 
for VACNF NEA. However, for the VACNF NEA at amplitude larger than 0.15 V, the value of 
the peak current density deviated from the linear relationship and the raw ACV peak became 
broad and unstable (Figure A.3). For this reason, we choose amplitude at 0.15 V as the optimum 
working amplitude in all the following ACV measurements for legumain activity study. For 
cathepsin B study, the tetrapeptide H2N-(CH2)4-CO-Leu-Arg-Phe-Gly-NH-CH2-Fc was 
immobilized on the VACNF NEA, giving very similar ACV properties with slightly different 
optimum AC frequency (800 Hz) and amplitude (0.15 V), respectively (see Figure A.4). These 
optimum parameters were used in the following kinetic study on cathepsin B activities.  
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Figure 3.5 (a) The change of the peak current (ip,acv) of H2N-(CH2)4-CO-Leu-Arg-Phe-Gly-NH-
CH2-Fc immobilized on a VACNF NEA in continuously repeated ACV measurements while 25 
µL of 9.8 ng·µL
-1
 (338 nM) cathepsin B in the activation buffer consisting of 5 mM DTT and 25 
mM MES (pH 5.0) was added into the electrochemical cell containing 250 µL of 25 mM MES 
(pH 5.0). All ACV measurements were carried out at f = 800 Hz and AC voltage amplitude V0 = 
150 mV. (b) ACV curve measured at the time of 20 minute immediately after the cathepsin B 
solution was added into the electrochemical cell. (c) Five representative background-subtracted 
ACV curves measured at 20 (black), 25 (red), 30 (blue), 40 (green) and 75 minute (pink), 
respectively, showing the decrease of ip, acv due to enzymatic cleavage. 
Figure 3.5 shows the change of peak current (ip,acv) over time during continuously 
repeated ACV measurements with Fc-linked tetrapeptide (H2N-(CH2)4-CO-Leu-Arg-Phe-Gly-
NH-CH2-Fc) immobilized on a VACNF NEA. The initial signal was quite stable, with only slow 
drifting. At ~20 minute, a solution of 25 µL of 9.8 ng·µL
-1
 (338 nM) cathepsin B in the 
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activation buffer was added into the electrochemical cell, giving a final enzyme concentration of 
30.7 nM. Due to the disturbance to in electrolyte, the ACV peak current jumped up and then 
followed by an exponential decay. Figure 3.5b shows the ACV curve measured at 20 minute, 
immediately after the cathepsin B solution was added. A clear peak at around 0.25 V confirms 
the immobilization of Fc-linked tetrapeptide on the electrode surface. Figure 3.5c further 
illustrates the representative background-subtracted ACV curves corresponding to 0, 5, 10, 20 
and 55 minutes, respectively, after adding the cathepsin B solution. The peak current clearly 
decreased over time and the peak position slowly shifted from 0.27 V to 0.18 V. Two control 
experiments (Figure A.5) were carried out and confirmed that the exponential decay in ip,acv was 
truly attributed to the kinetics of enzymatic cleavage of the peptide. First, 25 µL of blank 
activation buffer, i.e. 5 mM DTT and 25 mM MES (pH 5.0), was added into the electrochemical 
cell prefilled with 250 µL of electrolyte (25 mM MES (pH 5.0)). The disturbance to the ACV 
signal was negligible in this process. Second, a solution of 25 µL of activation buffer containing 
deactivated cathepsin B (which was confirmed with the fluorescence assay) was added into the 
electrochemical cell in the similar way as in the first case. Neither case showed the characteristic 
exponential decay observed when the activated enzyme was introduced. It is clear that the 
exponential decay was due to enzymatic cleavage to the tetrapeptide substrate by cathepsin B.  
 3.3 Modified Michaelis-Menten model for heterogeneous enzymatic reaction 
The observed proteolysis kinetics may be explained with a modified Michaelis-Menten 
model for heterogeneous enzymatic reactions:
147
                 
                                     , PP  E  ES 
1
1 S  E sss  
catk
-k
k
                                         (3.1)                                                                                                                                                                                                                                                                                                                                                                                   
39 
where E, Ss, ESs, Ps and P represent the enzyme, the surface-bound peptide substrate, the 
enzyme-substrate complex on the electrode surface, the surface-attached product, and the 
product released to solution, respectively. The reaction rate can be defined as 
                                   ,
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]E[
0m
0


 sScatsPsS
Γk
dt
dΓ
dt
dΓ
υ                                                (3.2) 
where kcat is the dissociation rate constant, Km = (kcat+k-1)/k1 is the Michaelis-Menten constant, 
and Ss and Ps represent the surface densities of original and reacted peptide substrates, 
respectively. At low enzyme concentrations with [E0] << Km, an approximate relationship can be 
obtained as  
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The reaction rate υ (or -dSs/dt) is a time-dependent quantity proportional to the change in 
electrochemical signals (dE/dt), where E is the kinetic electrochemical signal corresponding to 
the peak current ip in ACV measurements. As a result the slope of (dE/dt) versus the time-
dependent Ss will be equal to (kcat/Km)[E0], namely 
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Thus, by rearranging the kinetic electrochemical data, we can derive the value of 
“specificity constant” kcat/Km which is commonly used to represent the catalytic efficiency of 
enzymes.  
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 3.4 Analyses of legumain and cathepsin B activity 
 
Figure 3.6 Replot of the data presented in Figure 3.5. (a) Decrease of the quantity of surface 
adsorbed Fc (i.e. Γsurf) during enzymatic cleavage of the tetrapeptide after adding the cathepsin B 
solution. (b) Plot of the reaction rate (vi) versus the quantity of surface adsorbed Fc (Γsurf) during 
the enzymatic reaction.  
To further analyze the kinetic enzymatic process, the peak current in ACV was converted 
into the quantity of surface adsorbed Fc (i.e. Γsurf) based on
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where the AC frequency f was 800 Hz and the amplitude of the AC voltage V0 was 150 mV. 
Although the Γsurf value derived with Equation 3.5 is known to be smaller than that obtained with 
other methods, particularly at high frequencies, the linear relationship between ip,acv and Γsurf 
remains true. The deviation of the proportional coefficient from the true value is cancelled in 
later steps and does not affect the final results. As shown in Figure 3.6a, the kinetic data can be 
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fitted with an exponential decay superimposed on a linear curve corresponding to the slow 
baseline drift. The fitting equation is  
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From equation 3.6, the reaction rate vi at different Γsurf can be calculated. The results were 
presented in Figure 3.6b, which appeared to be a linear curve in the high Γsurf region. This linear 
curve is fitted by equation 
                                                   
183 1020.11015.1   surfiv  .                                        (3.7) 
As mentioned earlier, both vi and Γsurf are proportional to ip,acv. The slope of vi versus 
Γsurf, however, is independent of the exact proportional coefficient since it presented in both vi 
and Γsurf and is thus cancelled. Therefore, we can derive the exact slope without being affected 
by the ACV experimental conditions. Equation 3.7 gives a slope of 1.15 x 10
-3
 s
-1
, which equals 
to (kcat/Km)[E0] as described in Equation 3.3. With [E0] = 30.7 nM, the value of the “specificity 
constant” kcat/Km can be calculated as 3.8 x 10
4
 M
-1
s
-1
. This value is close to the value of 2.3 x 
10
4
 M
-1
s
-1
 derived from the comprehensive analysis with the fluorescence assay in a series of 
peptide substrate concentrations (Figures A.6 & A.7). It is also within the range reported in 
literature which varies from ~2 x 10
3
 M
-1
s
-1
 to ~7 x 10
6
 M
-1
s
-1
. 
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Figure 3.7 (a) The change of the peak current (ip,acv) of H2N-(CH2)4-CO-Ala-Ala-Asn-Leu-NH-
CH2-Fc immobilized on a VACNF NEA in continuously repeated ACV measurements while 11 
µL of 90.9 ng·µL
-1
 (1.90 µM) legumain in the activation buffer consisting of 50 mM 
CH3COONa (pH = 4.0, adjusted by adding acetic acid) and 100 mM NaCl was added into the 
electrochemical cell containing 250 µL of 50 mM MES (pH 5.0) and 250 mM NaCl. All ACV 
measurements were carried out at f = 1750 Hz and AC voltage amplitude V0 = 150 mV. (b) 
Replot of the data presented in figure (a) showing the reduction of the quantity of surface 
adsorbed Fc (i.e. Γsurf) during enzymatic cleavage of the tetrapeptide after adding the legumain. 
(c) Plot of the reaction rate (vi) versus the quantity of surface adsorbed Fc (Γsurf) during the 
enzymatic reaction. 
Figure 3.7 shows the ACV measurements with H2N-(CH2)4-CO-Ala-Ala-Asn-Leu-NH-
CH2-Fc immobilized on a VACNF NEA. Comparing to cathepsin B, the change of peak current 
corresponding to the cleavage by legumain was smaller, likely due to the difference in the 
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enzyme activity. None of the two control experiments in Figure A.8 by adding the blank 
activation buffer and the buffer containing deactivated legumain (confirmed with fluorescence 
assay), respectively, showed the characteristic exponential decay in ip,acv. The former caused 
negligible disturbance to the electrochemical signal. The latter caused the ip,acv to slowly rise by 
~5% after 5 minutes and then became stabilized, which might be attributed to the  disturbance to 
the tetrapeptide conformation on the electrode surface. 
The data in Figure 3.7b can be fitted with the following equation: 
15201101
 
16 1075.31036.41023.3 







  te
t
surf
                                    (3.8) 
where the time constant is 1101 s (~18 min.), indicating that the reaction is quite slow. It 
normally took ~1 hour to complete the kinetic measurement. This was found to be limited by the 
low enzymatic activity of legumain. However, it was still possible to extract the faradaic signal 
of Fc from the varying background with the ACV measurements. Figure 3.7c gives a linear curve 
fitted by equation 184 1030.21030.6   surfiv with the slope of 6.30 x 10
-4
 s
-1
 at [E0] = 80.1 
nM. From this analysis, the value of the kcat/Km can be calculated as 7.9 x 10
3
 M
-1
s
-1
. This value 
is higher than the value of 4.3 x 10
3
 M
-1
s
-1
 derived from the comprehensive analysis using the 
fluorescence assay (Figures A.9 & A.10) and the specifications provided by the vendor (R&D 
Systems).  
The kinetic measurements with ACV for both cathepsin B and legumain were repeated at 
least three times under similar conditions as those in Figure 3.5 and Figure 3.7. The results were 
consistent and reproducible. More comprehensive measurements at varied enzyme 
concentrations and peptide lengths will be reported in future studies. Table 3.1 summarizes the 
statistical values of the specificity constant kcat/Km derived from both electrochemical method 
44 
using ACVs on VACNF NEAs in comparison with the fluorescence assay based on a series of 
substrate concentrations in solution, for both legumain and cathepsin B. Interestingly, the 
electrochemical method gave higher kcat/Km values for both of legumain and cathepsin B than the 
fluorescence assay. In contrast, other studies using macroscopic electrodes found that the 
electrochemically measured kcat/Km was normally lower than solution based assays, primarily 
due to the steric effects which lower the access of enzyme to the peptides attached to the flat 
surface.
64, 131
 The results confirmed that the small radius in VACNF NEAs helped to eliminate 
the steric hindrance. The peptide substrates for the fluorescence assay consisted of only 3 and 2 
amino acids, respectively, which were also expected to have lower binding affinity than the 
tetrapeptides used for our electrochemical measurements.  
Table 3.1 Comparison of the specificity constant kcat/Km for legumain and cathepsin B, derived 
from the electrochemical method (i.e. ACV on VACNF NEAs) and the fluorescence assay in 
solutions.  
Enzyme Peptide Sequence kcat/Km (M
-1
s
-1
) 
Legumain 
(FL
a
) Ala-Ala-Asn-AMC (4.3 ± 0.6) x 10
3
 
(EC
b
) Ala-Ala-Asn-Leu-NH-CH2-Fc (11.3 ± 3.8) x 10
3
 
Cathepsin B 
(FL) Leu-Arg-AMC (2.3 ± 1.7) x 10
4
 
(EC) Leu-Arg-Phe-Gly-NH-CH2-Fc (4.3 ± 0.8) x 10
4
 
    
a
FL: fluorescence; ↓: cleavage site. The fluorescence data were derived from the analysis in 
Figures A.6, A.7, A.10 and A.11. 
b
EC: electrochemistry. The electrochemical data were statistical value over at least duplicated 
experiments. 
The values of the specificity constant kcat/Km for cathepsin B by both electrochemical and 
fluorescence assays are about 5 times of that of legumain. For ACV measurements, this helps to 
reduce the time constant for the exponential decay and makes the experiment easier and more 
reliable. As a result, lower enzyme concentration can be measured. From these results, it can be 
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concluded that the ACV would work even better for measuring proteases with the kcat/Km values 
higher than ~4 x 10
4
 M
-1
s
-1
. But even proteases with relatively low specificity constant (such as 
legumain and cathepsin B) can still be reliably measured. Even though the required enzyme 
concentration was ~5 to 10 times higher than that by the fluorescence assay, the electrochemical 
method has a potential advantage that simultaneous detection of multiple proteases in a small 
volume is possible, attributed to its localized sensing mechanism using surface-attached peptides. 
Further investigation is in progress to assess the cross-reactions between different enzyme-
substrate pairs. 
The vendor suggests that legumain cleaves peptide bonds with asparagine (Asn) at the P1 
position while it has been reported that cathepsin B cleaves peptide or AMC bonds with arginine 
(Arg) at P1 site.
151
 To confirm the cleavage site, we have incubated each tetrapeptide with 
legumain and cathepsin B and measured the products with HPLC. As shown in Figure A.11 and 
Figure A.12, the HPLC graphs of the cleaved products were directly compared with those of the 
pure tetrapeptides and synthesized fragments (mono amino acid or dipeptide). The cleaved 
products were further validated with mass spectrometry. These experiments clearly demonstrated 
the cleavage site as listed in Table 3.1. Interestingly, even after incubating for 2 hours, the 
cleaved tetrapepetide concentration was only ~1/5 of the total concentration for legumain and 
~3/4 for cathepsin B. The fluorescence assay reported earlier is sensitive to the absolute amount 
of cleaved products while the electrochemical assay is sensitive to the percentage of the cleavage 
to the surface-attached peptide. The large amount of starting peptides used in the fluorescence 
assay partially contributed to its capability to measure lower enzyme concentrations. The 
electrochemical method, however, has advantage for miniaturization and multiplexing which 
may be critical for rapidly screening multiple proteases in disease diagnosis. It is noteworthy that 
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the kcat/Km values of legumain and cathepsin B are relatively low, but they have high biological 
significance respect to cancer diagnosis and treatment. The speed and required enzyme 
concentration in the electrochemical measurements can be significantly improved when this 
technique is used to detect other proteases with higher kcat/Km values, such as trypsin at (1.44 ± 
0.1) x 10
6
 M
-1
s
-1
,
64
 α-thrombin at (1.0 ± 0.2) x 106 M-1s-1,64 and plasmin at 6.7 x 105 M-1s-1.131 
In previous electrochemical detection of proteases including trypsin,
64
 a-thrombin,
64
 and 
plasmin,
131
 normal CV measurements on gold electrodes were used. This method was found not 
applicable on carbon electrode. As shown in Figure A.13, the Fc redox waves of the labeled 
tetrapeptide can be observed on the GCE, but the baseline currents were quite high, making it 
difficult to reliably extract redox signals. The previous studies on gold electrodes were able to 
block the nonfaradaic background current using close-packed self-assembled monolayer of small 
passivating alkane thiol molecules. The covalent bond of small passivating molecules does not 
allow them to move around to form a close-packed monolayer.  Thus there were many leaking 
pinholes in the passivation layer on GCE. This is even more severe on VACNF NEA due to the 
curvature and inhomogeneity at the CNF surface. As a result, it was not possible to use CV to 
measure the Fc signal on VACNF NEAs. ACV provides a necessary solution for the reported 
enzymatic study.  
While we have demonstrated that it is feasible to detect the enzymatic kinetics of both 
legumain and cathepsin B. It remains critical to evaluate the specificity for any practical 
applications. This will be carefully investigated in the future. Our preliminary data indicated that 
the specificity of protease detection using this reported method strongly depended on the value of 
the “specificity constant” kcat/KM. Cathepsin B has higher kcat/KM which resulted in ~75% of 
drop in the electrochemical signal due to cleavage to the designated tetrapeptide (see Figure 
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A.5). As a result, the exponential decay can be reliably measured, giving high specificity. In 
contrast, as shown in Figure A.14, the change of electrochemical signal is negligible using a 
tetrapeptide without Arg. For legumain, the low value of kcat/KM caused that the electrochemical 
signal only dropped by ~10% (see Figure 3.7a). The disturbance to the electrode during adding 
the enzyme solution caused uncontrollable fluctuation in the electrochemical signal. This limited 
precisely deriving the kcat/KM value. Therefore, the specificity for legumain is inconclusive at 
this stage and needs careful further study. But we can conclude that kcat/KM of (1.13 ± 0.38) x 10
4
 
M
-1
s
-1
 (as for legumain) is about the low limit for reliable protease measurements using the 
current setup.  
 3.5 Conclusions 
In summary, we have demonstrated that high-frequency ACV can be applied on 
embedded VACNF NEAs to measure the redox reaction of Fc attached to the exposed CNF tip 
through a tetrapeptide and linker molecule. Due to the additional capacitive current pathway 
enabled by the unique interior graphitic microstructure of the VACNFs, the optimum frequency 
giving the highest peak AC current for Fc on VACNF NEA was found to be 40 times of that on 
GCEs. The higher frequency afforded a larger ACV signal and shorter time for the ACV 
measurements. Thus the kinetics of proteolysis of the surface-attached peptides can be measured 
upon addition of two types of cancer related proteases, i.e. legumain and cathepsin B. The kinetic 
process can be analyzed with a heterogeneous Michaelis-Menten model to derive the “specificity 
constant” kcat/Km, which is (4.3 ± 0.8) x 10
4
 M
-1
s
-1
 for cathepsin B and (1.13 ± 0.38) x 10
4
 M
-1
s
-1
 
for legumain. These values are about 2 times of that measured with a fluorescence assay as well 
as the specifications provided by the vendor. The nanostructured electrode size clearly 
eliminated the steric effects for enzymatic reactions with surface-attached peptides. This is the 
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first example of the use of VACNF NEA on protease activity study. These VACNF NEA based 
electrochemical enzymatic biosensors can be potentially developed into portable multiplex 
electronic devices for rapid cancer diagnosis and treatment monitoring. Further study on the 
specificity and sensitivity of this VACNF NEA biosensor applied with biological samples is in 
progress toward this goal. 
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Chapter 4 - Quantitative electrochemical detection of cathepsin B 
activity in complex tissue lysates 
Reproduced in part by permission of Elsevier.  
Published as: Swisher, L. Z.; Prior, A. M.; Nguyen, T. A.; Hua, D. H.; Li, J. Biosens. 
Bioelectron. 2014, 56, 129-136.  
 4.1 Introduction 
Cathepsin B is a lysosomal cysteine protease which is highly expressed during cancer 
invasion and progression.
152-154
 Increased level of cathepsin B in tumors or in extracellular fluids 
can serve as prognostic factors for cancer patients.
155-156
 It has been reported that cathepsin B is 
overexpressed in many cancer types, such as laryngeal cancer, oral cancer, breast cancer and 
colorectal cancer, compared to that in normal tissue.
157-161
 Therefore simple and rapid detection 
of the expression level of cathepsin B, particularly quantitatively determine its enzymatic 
activity, is highly demanded for early diagnosis and treatment of cancers.
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Recently, we demonstrated a new approach by applying ACV on NEAs fabricated with 
embedded VACNFs to measure the activities of two cancer related proteases, legumain and 
cathepsin B.
1
 The proteolytic kinetics of both proteases can be approximately analyzed with a 
heterogeneous Michaelis-Menten model.
1, 162
 Cathepsin B is particularly interesting since its 
kcat/KM value was derived as (4.3 ± 0.8) x 10
4
 M
-1
s
-1
, about four times of that of legumain, and 
hence can be reliably measured in a wider concentration range.  
The ACV technique involved superimposing a sinusoidal AC voltage on the DC potential 
ramp, which can enhance the redox current from Fc moieties immobilized at the electrode 
surface by shuffling the electrons back and forth many times between the Fc moieties and the 
electrode.
47, 148
 Particularly, applying ACV on the VACNF NEAs enabled the use of much 
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higher AC frequencies than on conventional macroscopic GCEs.
47
 For Fc-appended tetrapeptide 
on VACNF NEAs, the maximum ACV peak current was at ~1,000 Hz, about 40 times of that on 
macro-GCEs.
1
 The enhanced electrochemical signal and higher temporal resolution (< 1 min) are 
critical for measuring the fast enzymatic kinetics in this study.  
However, the previous method
1
 was found unable to consistently compare data collected 
from different electrodes due to the variation in electrochemical signals. Here we report a refined 
method for analyzing the kinetic ACV data of proteolysis of Fc-peptide attached on VACNF 
NEAs. Consistent quantitative analyses of cathepsin B activity at varied concentrations have 
been established. In addition, two critical steps toward rapid multiplex cancer diagnoses have 
been achieved. First, we demonstrate that this detection method is applicable on the whole tissue 
lysate of normal human breast samples, the tissue lysate spiked with varied concentrations of 
purified cathepsin B and the tissue lysate after immunoprecipitation. The relative cathepsin B 
concentrations in these complex samples are clearly correlated with the exponential rate. Second, 
a 3 x 3 microarray containing nine independently addressed regular VACNF NEAs by e-beam 
lithography showed substantially enhanced performance than the previously used non-patterned 
random VACNF NEAs. The measured activity of cathepsin B appeared to be much higher due to 
the smaller and well-defined CNF tips. These results demonstrated the great potential for this 
nanoelectronic method as a portable multiplex technique for simultaneously detecting a large 
number of distinct proteases in a minute drop of serum or lysate sample. This may enable quick 
analyses of a patient’s protease profile, which is critical for rapid cancer diagnosis and treatment 
monitoring.  
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 4.2 Quantitative analyses of purified cathepsin B activity 
The insert of Figure 4.1a illustrates the principles of electrochemical assay for measuring 
the enzymatic activity of cathepsin B using VACNF NEAs. The tetrapeptides Leu-Arg-Phe-Gly 
labeled with electroactive Fc at the distal end are immobilized on the VACNF NEAs. Fc 
provides a reliable oxidation peak at ~0.25 V versus Ag/AgCl (3 M KCl) in ACV measurements. 
In our previous report
1
, we have confirmed with HPLC and MS analyses that cathepsin B 
specifically cleaved the tetrapeptide at the site between arginine and phenylalanine. This releases 
the fragment containing Fc into the bulk solution and caused the peak current to decrease. The 
kinetics of the proteolytic reaction is monitored with continuously repeated ACV measurements. 
As reported in our previous studies
1, 47
, a noteworthy advantage of ACV technique on Fc-
attached VACNF NEAs is that the optimum AC frequency (800 to 1,800 Hz) was much higher 
than that on macro-GCEs (~40 Hz), leading to higher sensitivity and higher temporal resolution.  
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Figure 4.1 (a) A representative ACV of a random VACNF NEA immobilized with H2N-(CH2)4-
CO-Leu-Arg-Phe-Gly-NH-CH2-Fc measured at AC frequency f = 800 Hz and AC voltage 
amplitude V0 = 150 mV. Insert: Schematic of cathepsin B induced proteolytic cleavage of the 
tetrapeptide substrate. (b–d) Four representative background-subtracted ACVs from the 
continuously repeated ACV measurements after 25 µL of cathepsin B was added into the 
electrochemical cell. The final concentrations of cathepsin B were (b): 15.5 nM (0.5 ng·μL-1); 
(c): 30.7 nM (0.9 ng·μL-1); and (d): 62.1 nM (1.8 ng·μL-1), respectively. (E–G) The change of 
ACV peak current ip,acv versus the reaction time while the cathepsin B solution at the 
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concentration corresponding to (b–d) was added to the electrochemical cell. The continuous lines 
are fitting curves to the proteolysis using Equation 4.1. 
Figure 4.1a shows a representative ACV curve of H2N-(CH2)4-CO-Leu-Arg-Phe-Gly-
NH-CH2-Fc immobilized on a random VACNF NEA. The AC peak current ip,acv can be derived 
by subtracting a linear background. Figures 4.1b-d show four representative background-
subtracted ACV curves corresponding to 0, 20, 40 and 60 min, respectively, after adding the 
purified cathepsin B solution at three different final concentrations. The background-subtracted 
peak current ip,acv clearly decreased with the reaction time while the peak position slowly shifted 
from ~0.25 to ~0.15 V. Figures 4.1e-g illustrate the value of ip,acv from all ACVs versus the 
reaction time t. The value of ip,acv was relatively stable at the beginning. Adding the cathepsin B 
solution at t = 0 caused some disturbance to the ip,acv signal. Following that, all curves showed an 
exponential decay versus the reaction time which can be fit with: 
                                                 
c)  (b  )/exp( 0t  ttii  .                          (4.1) 
The values of the fitting parameters to Figure 4.1e–d are listed in Table B.1. Apparently, 
the value of i0 correlated with the total amount of surface-functionalized peptide-Fc
47, 148
, which 
varied with the density and exposed length of VACNFs in the NEAs. The term (bt + c), whose 
nature was not fully understood in our previous study
1
, was found due to the Fc residues that 
were not cleavable by the protease. A large portion of them was attributed to physically trapped 
peptide-Fc at the Cr or embedded CNF surface due to the defects and pores in the SiO2 insulating 
layer. Figure B.2 shows the ACV feature of physically trapped peptide-Fc on a random VACNF 
NEA by simply soaking the chip in 1.0 mM peptide-Fc solution for 2 hrs. There was also a 
possibility that some covalently attached peptide-Fc molecules might lie tightly on the VACNF 
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surface and cannot be cleaved by the protease due to the steric hindrance. Both factors may lead 
to the negative shift of ACV peak potential in Figure 4.1b–d.  
Two “negative control” experiments were carried out to ascertain that the exponential 
decay of the ip,acv signal was attributed to specific proteolysis of cathepsin B by using a non-
relevant peptide-Fc substrate H2N-(CH2)4-CO-Ala-Ala-Asn-Leu-NH-CH2-Fc and a peptide-Fc 
substrate with the specific cleavage site (i.e P1) –Arg- replaced by –Asn-, i.e. H2N-(CH2)4-CO-
Leu-Asn-Phe-Gly-NH-CH2-Fc. As shown in Figure B.3a&b, the peak current ip,acv of these two 
tetrapeptides did not show the characteristic exponential decay while the activated cathepsin B 
was added into the electrochemical cell.  
Apparently, the exponential decay of the ip,acv value after adding the protease represents 
the proteolysis kinetics. However, though each curve in Figure 4.1e-g can be analyzed 
separately, the raw ip,acv(t) values cannot be directly compared due to the variations in Fc-peptide 
quantity and background level from sample to sample. In order to normalize these varying 
factors, we define a new function S, referred as “extracted proteolytic signal”, with 
                               
)/exp( c)]/  b([  0t titiS  .                                                       (4.2) 
The extracted function S is essentially the exponential component of the kinetic data, 
whose decay time constant τ is directly related to the protease activity, as will be discussed later. 
As shown in Figure 4.2, the proteolytic measurements of different random VACNF NEAs at 
three cathepsin B concentrations are normalized to the same fractional scale using S, with all 
curves passing through (t = 0, S = 1.0). This allows clear view of the decay rate from different 
samples. The increase in cathepsin B concentration caused the function S to decay faster, giving 
smaller decay time constant τ and higher protease activity. This new method is critical for later 
studies requiring quantitative comparison of data from a large set of electrodes. 
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Figure 4.2 The proteolysis kinetics represented by the extracted proteolysis signal S = (it - ib)/i0 
vs. the reaction time after adding purified cathepsin B into the electrochemical cell. The final 
concentrations of cathepsin B are 15.5, 30.7, and 62.1 nM, respectively. Each set of data was 
fitted with a simple exponential decay. 
From our previous report
1
, the proteolysis kinetics can be analyzed with a modified 
Michaelis-Menten model for heterogeneous enzymatic reactions 
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:                 
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where E, Ss, ESs, Ps and P represent the enzyme, surface-bound peptide substrate, enzyme-
substrate complex on the electrode surface, surface-attached product, and product released to 
solution, respectively. The reaction rate υ can be defined as 
                                             
,
][EK
][Ek
dt
d
0M
0cat




 SS
SS
υ                                               (4.4) 
where ΓSs represents the surface density of active peptide substrate, kcat is the dissociation rate 
constant and KM = (kcat+k-1)/k1 is the Michaelis-Menten constant, respectively. Since “extracted 
56 
proteolytic signal” S is proportional to the surface densities of Fc-peptide substrates (i.e. ΓSs S), 
Equation 4.4 can be rewritten as Equation 4.5 and, at low enzyme concentrations ([E0] << KM), 
an approximate relationship can be obtained as  
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The value of (-dS/dt) can be derived from Figure 4.2 and plot versus S in Figure 4.3a. 
Combining Equations 4.2 and 4.5, it gives 
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Therefore, the measured quantity (kcat/KM)·[E0] can be represented by 1/τ or the slope of 
Figure 4.3, with smaller τ giving larger (kcat/KM)·[E0]. The statistical value of (kcat/KM)·[E0] 
derived from the slope of each lines in Figure 4.3a (i.e. -dS/dt versus S) was (7.45 ± 3.53) x 10
-4
, 
(1.25 ± 0.30) x 10
-3
 and (2.15 ± 0.37) x 10
-3
 s
-1
 from nine experiments with enzyme 
concentration at 15.5, 30.7 and 62.1 nM, respectively. As shown in Figure 4.3b, the derived 
quantity (kcat/KM)·[E0] is linearly proportional to the enzyme concentration [E0], consistent with 
the theoretical model. Since [E0] was known in the measurements shown in Figure 4.1&4.2, one 
can easily derive the concentration-independent “specificity constant” kcat/KM which is 
commonly used to represent the fundamental catalytic efficiency of different enzymes.  
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Figure 4.3 (a) Plot of the reaction rate -dS/dt versus extracted proteolysis signal S = (it-ib)/i0 at 
different cathepsin B concentrations. (b) Plot of (kcat/KM)·[E0] with respect to cathepsin B 
concentration [E0] in the proteolytic reactions. The error bars are the standard deviation of the 
results from at least triplicated experiments.  
The calculated kcat/KM values at three cathepsin B concentrations were very close to each 
other, giving an average value of 4.11 x 10
4
 M
-1
s
-1
 and a standard deviation of 6.66 x 10
3
 M
-1
s
-1
. 
Alternatively, fitting the data points in Figure 4.3b with a straight line passing through the origin 
gave a more accurate kcat/KM value of (3.68 ± 0.50) x 10
4
 M
-1
s
-1
 that incorporated the results 
from all nine experiments at three discrete cathepsin B concentrations. These kcat/KM values are 
more accurate than our previous analyses
1
 based on ACV measurements at a single enzyme 
concentration. The kcat/KM of the same batch of cathepsin B derived from nine fluorescence 
experiments right before the electrochemical measurements was (9.6 ± 4.1) x 10
4
 M
-1
s
-1
, showing 
much larger standard deviation. However, all values are within the range of ~2 x 10
3
 M
-1
s
-1
 to ~7 
x 10
6
 M
-1
s
-1
 in literature
147, 149-150
 with a more extensive list showing in Table B.2. Importantly, 
the results confirmed that the kcat/KM value by ACV measurements remained constant as the 
cathepsin B concentration varied, establishing a method to determine the cathepsin B activity in 
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an unknown sample by dividing the measured (kcat/KM)·[E0] with the above kcat/KM value. 
 4.3 Detecting cathepsin B activity in complex tissue lysates 
Normal human tissues may contain many proteases including cathepsin B and their 
expression at higher level is expected in cancerous tissues. To demonstrate that ACV coupled 
with VACNF NEAs is viable for detecting protease activities in complex human samples, we 
have carried out three sets of measurements using lysates from human breast tissue. The 
cathepsin-B-specific tetrapeptide H2N-(CH2)4-CO-Leu-Arg-Phe-Gly-NH-CH2-Fc was 
immobilized on random VACNF NEAs. The human breast whole tissue lysate (adult normal) 
was first treated with the activation buffer similar to the purified cathepsin B experiments.  25 µL 
of  the activated lysate solution was then added into the electrochemical cell containing 250 µL 
of 25 mM MES (pH 5.0) while the ACV measurement was continuously repeated. In Figure 4.4a, 
the final concentrations of the lysate were 20.0 µg·mL
-1
 and 29.1 µg·mL
-1
, diluted by 245 and 
168 fold, respectively from the purchased tissue lysate stock solution. Both lysate samples 
caused exponential decay after being added into the electrochemical cell, as shown in the 
“extracted proteolytic signal” S = (it - ib)/i0 with ib = bt + c. The fitted time constants are τ0 = 725 
s and τ0’ = 1647 s at the lysate concentration of 29.1 and 20.0 µg·mL
-1
, respectively. The derived 
(kcat/KM)·[E0] values are 6.04 x 10
-4 
s
-1
 for 20.0 µg·mL
-1
 tissue lysate and much higher at 1.38 x 
10
-3
 s
-1
 for 29.1 µg·mL
-1
 tissue lysate. Using kcat/KM = (3.68 ± 0.50) x 10
4
 M
-1
s
-1
 derived from the 
purified cathepsin B solutions in Figure 4.3, the equivalent cathepsin B concentrations were 
calculated as ~(16.4 ± 2.2) nM in the 20.0 µg·mL
-1
 tissue lysate, and ~(37.5 ± 5.1) nM in the 
29.1 µg·mL
-1
 tissue lysate. Due to the existence of the experimental deviation and activity 
variation of biology sample, they did not present a perfect linear relationship but were close.   
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Figure 4.4 The proteolysis curves of (a) 20.0 µg·mL
-1
 (pink diamond) and 29.1 µg·mL
-1
 (black 
square) of the whole breast tissue lysate (normal adult human); (b) 29.1 µg·mL
-1
 whole tissue 
lysate (black square) and this tissue lysate spiked with 0.9 µg·mL
-1
 (30.7 nM) (red dot) and 0.5 
µg·mL
-1 
(15.5 nM) (blue triangle) cathepsin B, respectively; and (c) 29.1 µg·mL-1 tissue lysate 
before (black square) and after four rounds of immunoprecipitation (4IP) in order to deplete the 
cathepsin B (green dot). All ACV measurements were carried out at f = 800 Hz and AC voltage 
amplitude V0 = 150 mV. (d) Western blot analysis using cathepsin B antibody: Lysate lane – 
25.0 µg of the original whole tissue lysate; Pellet lane – the immunoprecipitated fraction of 0.5 
mg of tissue lysate using cathepsin B antibody; Supernatant lane – the supernatant fraction after 
four rounds of immunoprecipitation. The proenzyme cathepsin B is ~37 kDa and the active 
cathepsin B is ~25 kDa. 
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As 15.5 and 30.7 nM purified cathepsin B were spiked into the 29.1 µg·mL
-1
 tissue lysate, 
the decay became faster, giving τ1 = 433 s and τ2 = 213 s, respectively (Figure 4.4b). Clearly, 
substantial proteolysis was catalyzed by cathepsin B. To further confirm that the measured decay 
was from the specific proteolysis of peptide-Fc by cathepsin B, an immunoprecipitation (IP) 
assay was employed to partially remove cathepsin B from the tissue lysate. The exponential 
decay was indeed much slower, giving τ4 = 1246 s (Figure 4.4c), but some substantial decay 
feature was retained. It is likely that some cathepsin B still retained in the tissue lysate after four 
rounds of IP but the level was below the sensitivity of Western blot analysis shown in Figure 
4.4d. It is also possible that other proteases (particular other cathepsins, such as cathepsin L and 
V) may cleave the tetrapeptide although the catalytic activity may be lower.  
Quantitative estimation of cathepsin B activity in the tissue lysate can be made based on 
the results shown in Figure 4.4b. First, according to Equation 4.6, we can derive the difference 
between the 15.5 nM spiked and unspiked samples as:  
(kcat/KM)·([E0] + 15.5 nM) – (kcat/KM)·[E0] = 1/τ1 – 1/τ0 = 9.30 x 10
-4 
s
-1
,                                 (4.7) 
which gives kcat/KM = 6.0 x 10
4
 M
-1
s
-1
. This value is slightly higher than the value (4.11 ± 0.67) x 
10
4
 M
-1
s
-1 
obtained with purified cathepsin B in buffer solutions as discussed above. For the 
tissue lysates with and without IP procedure, we have 
                                   (kcat/KM)·Δ[E0] = 1/τ0 – 1/τ4 = 5.77 x 10
-4 
s
-1
.                                          (4.8) 
Thus the difference in cathepsin B concentration Δ[E0] is equivalent to ~14 ± 2.3 nM 
cathepsin B in buffer solution if we use the value kcat/KM = (4.11 ± 0.67) x 10
4
 M
-1
s
-1
 discussed 
above.  Though refinements are needed to reduce the error bar, it is clear that this method is 
applicable in complex tissue lysate samples. This study established a critical step toward 
developing meaningful diagnosis tools. To our knowledge, this is the first time that the activity of 
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a protease has been quantitatively determined by electrochemical methods with complex whole 
tissue lysates.  
The cathepsin B activity in the normal human breast whole tissue lysate was also 
validated by the fluorescence method using a short peptide substrate Z-Leu-Arg-AMC. The very 
small exponential curvature in Figure B.4 gave a much lower value of (kcat/KM)·[E0] (~4.98 x 10
-
5
 s
-1
) than that obtained from the electrochemical measurement (~1.38 x 10
-3
 s
-1
), although the 
lysate concentration was much higher (0.24 mg·mL
-1
 vs. 29.1 µg·mL
-1
). But the lysates spiked 
with 11.9 and 23.9 nM purified cathepsin B showed clear exponential increases in fluorescence 
signal (Figure B.5) due to proteolysis, which validated that the electrochemical signal was indeed 
due to cathepsin B. 
 4.4 Toward multiplex detection with regular VACNF NEAs 
In long term, regular VACNF NEAs can be mass-produced as multiplex chips on 
independently addressed microelectrode pads using UV- and e-beam lithography
119
. Such chips 
can be integrated into portable electronic systems for profiling a set of proteases. Figure 4.5a and 
B.1 show nine 200 µm x 200 µm microelectrode pads of ~100 nm-thick Cr film in a 3 x 3 array 
on a SiO2-covered Si wafer. VACNFs were grown in regular 1 μm x 1 µm lattice on these 
microelectrode pads to form embedded NEAs which were independently connected with the 
measuring circuits through larger (1 mm x 1 mm) contact pads at the top of Figure B.1a (not 
shown). Figure 4.5b shows the zoom-in image of exposed VACNF tips of ~100 nm in diameter 
and ~150 nm length protruding over the SiO2 matrix. Figure B.6a shows the CVs of a 50 mM 
K3Fe(CN)6 solution from all nine VACNF NEAs. Clearly, they all showed the characteristic 
sigmoidal shape with low background and almost identical limiting current, indicating the high 
uniformity of these NEAs. 
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Figure 4.5 SEM images at 45° perspective view of (a) a 3 x 3 VACNF NEA chip, and (b) the e-
beam patterned regular VACNF NEA partially embedded in SiO2 matrix at each microelectrode 
pad. (c) The extracted proteolysis signal S = (it-ib)/i0 was derived from continuously repeated 
ACV measurements while 25 µL of purified cathepsin B was added into the electrochemical cell 
to a final concentration of 30.7 nM (0.9 ng·μL-1). All ACV measurements were carried out at f = 
800 Hz and AC voltage amplitude V0 = 150 mV. 
The covalently attached tetrapeptide H2N-(CH2)4-CO-Leu-Arg-Phe-Gly-NH-CH2-Fc on 
the e-beam patterned regular VACNF NEA present a similar ACV peak at ~0.25 V as shown in 
Figure B.6c. The peak shape was much better defined than the random VACNF NEAs. Similar 
as before, the ACV peak can be extracted by subtracting a linear background. Figure B.6d shows 
that the ACV peak current monotonically decreased after a purified cathepsin B solution was 
added into the electrochemical cell to give a final concentration of 30.7 nM. The peak potential 
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also continuously downshifted to ~0.10 V. The completed kinetic curve of raw ip,acv during 
proteolysis is presented in Figure B.7a. The ip,acv amplitude decayed much faster in the initial 
reaction period but then leveled off after ~35 min. Similar to the random VACNF NEAs, the 
leveled ip,acv was attributed to physically trapped peptide-Fc in the SiO2 matrix as confirmed by 
the control experiment shown in Figure B.7b. While such background can be reduced in the 
future by improving SiO2 deposition and passivation, it can be easily excluded using the 
“extracted proteolysis signal” S = (it-ib)/i0 discussed earlier.  
The kinetic curves of S vs. the reaction time after adding 30.7 nM purified cathepsin B is 
shown in Figure 4.5c. The fitted exponential decay time constant τ was 353 s, clearly smaller 
than 800 ± 192 s obtained with random VACNF NEAs at the same cathepsin B concentration. 
From either the fitted slope of –dS/dt versus S or τ value, (kcat/KM)·[E0] was calculated as 2.81 x 
10
-3
 s
-1
, about twice of the statistical value (1.25 ± 0.30) x 10
-3
 s
-1
 on the random VACNF NEA 
at 30.7 nM cathepsin B concentration. Accordingly, the specificity constant kcat/KM was 9.2 x 
10
4
, about twice of (4.11 ± 0.67) x 10
4
 M
-1
s
-1
 measured with random VACNF NEAs. Clearly, the 
regular VACNF NEAs worked much better than the random VACNF NEAs. The smaller 
diameter (~100 nm vs. 150 nm) may help to reduce the steric hindrance for enzymes to interact 
with the immobilized peptide. The uniform size and exposed length as well as the regular 
spacing of the CNFs made the regular VACNF NEAs more reproducible and perform better than 
the random VACNF NEAs. 
 4.5 Conclusions 
We have demonstrated electrochemical detection and kinetic analysis of cathepsin B 
activity in proteolysis of Fc-appended tetrapeptides that are immobilized on VACNF NEAs 
using enhanced AC voltammetry. A normalization algorithm was used to extract the proteolysis 
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signal from the largely varied raw data, which enabled consistent comparison and quantitative 
analyses of cathepsin B activity. This algorithm was first validated with purified cathepsin B 
solutions and then demonstrated in complex lysates of human breast tissue, the lysates spiked 
with purified cathepsin B, and the immunoprecipitated lysate. The cathepsin B concentration in 
normal tissue lysate can be quantitatively assessed by comparing these results. The regular 
VACNF NEAs fabricated with precise e-beam lithography showed faster kinetics of cathepsin B 
proteolysis, illustrating the potential for further improving detection sensitivity. This 
electrochemical method has great potential as a portable multiplex system for simple and rapid 
protease profiling of lysate, serum, or blood samples, which may be used in cancer diagnosis and 
treatment monitoring.  
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Chapter 5 - Quantitative electrochemical detection of cathepsin B 
activity in breast cancer cell lysates toward identification of cancer 
formation 
Reproduced in part from manuscript submitted by Swisher, L. Z.; Prior, A. M.; 
Gunaratna, M. J.; Shishido, S.; Madiyar, F.; Nguyen, T. A.; Hua, D. H.; Li, J. (under review) 
 5.1 Introduction 
Breast cancer is the most common type of cancers, with about 235,000 new cases 
expected in the United States in 2014, followed by prostate and lung cancer.
25
 The most useful 
prognostic parameters for cancer recurrence and progression are the tumor grade, the depth of 
tumor penetration (stage) and the presence of carcinoma in situ.
163
 Quantitative detection of 
molecular biomarkers that are involved in breast tumor progression is another important avenue 
for cancer diagnosis and treatment. It is known that cancer metastasis involves proteases, a group 
of enzymes that cause proteolysis to degrade the extracellular matrix (ECM) components and 
intercellular cohesive structures of neighboring cells leading to the activation of growth and 
angiogenic factors,
164-165
 which could serve as biomarkers for diagnosis.
49 
Among them, 
cathepsin B is a representative prognostic marker for human lung cancer
57
 and breast cancer.
166
  
Cathepsin B is a papain-family cysteine protease synthesized as glycosylated proenzyme 
of ~37 kDa and subsequently converted to the active form of ~25 kDa [by sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE)] after the proteolysis of the signal 
sequence.
167-168
 Of the cysteine proteases, cathepsin B has been most often implicated in invasive 
and malignant phenotype of tumors including brain, breast, lung, pancreas, bladder, prostate and 
stomach.
169
 ELISA has been commonly used to measure the cathepsin B concentrations in urine, 
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serum, and tissue lysates. Kotaska et al. found that cathepsin B concentrations have been 
significantly elevated in the serum and urine samples from bladder cancer patients and correlated 
well with grading and invasivity of tumors.
163
 Chen’s group claimed that the serum level of 
cathepsin B was significantly higher in the lung cancer patients compared to the healthy 
controls.
170
 Using immunochemical staining of tissue section and immunoblotting of cell lysates, 
Nouh et al. found that there was a positive correlation between the expression of cathepsin B and 
the number of positive metastatic lymph nodes in inflammatory breast cancer.
166
 By studying the 
microdissected frozen tissue sections of human tumors from colon and breast carcinoma, a group 
of researchers found a significant increase in the level of cathepsin B in regions of invasive 
tumor as compared to normal epithelium from the same patients.
171
  
Although ELISA and immunohistochemical methods can sensitively detect the 
concentration of specific proteases, they are typically time-consuming and can only measure one 
protease each time. In contrast, electrochemical technology has superior advantages such as its 
simple electronic readout and potential for simultaneous detection of multiple proteases using an 
electrode array, making it more suitable for rapid point-of-care diagnosis, treatment monitoring, 
and drug (protease inhibitor) screening. In addition, it detects the activity instead of 
concentration of proteases, which is more relevant to biological processes. However, there is 
very limited study of the activities of cancer-related proteases in complex human tissues or 
cancer cell lysates using electrochemical methods. In previous studies, we have demonstrated an 
electrochemical technique in detecting the proteolytic kinetics of two cancer-related proteases 
legumain and cathepsin B in purified solutions and complex whole tissue lysates, respectively, 
using NEAs fabricated with VACNFs a special type of carbon nanotubes.
1-2
  Specific 
tetrapeptides with a Fc group at the distal end were attached to the exposed VACNF tip and 
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selectively cleaved by the proteases. The unique structure of VACNFs allowed using a high-
frequency (~1 kHz) ACV to monitor the small electrochemical signal from Fc.
1-2, 47, 57
 In this 
report, we further apply this technique on detection of cathepsin B activities in four types of cell 
lysates including normal and breast cancer cells. The cathepsin B activities were found increased 
from normal to cancer cells and reached highest value in metastatic cancer cell lysate. A specific 
inhibitor clearly suppressed the activity of cathepsin B in the cell lysate. Our results showed that 
this NEA-based electrochemical method has great potential as a portable multiplex system for 
simple and rapid protease profiling of lysate, serum or urine samples toward early cancer 
diagnosis, treatment monitoring, and drug screening.  
 5.2 Cell characterization: Western blot analysis and IP assay    
The expression of cathepsin B in normal breast cells HMEC, non-tumorigenic breast cells 
MCF-10A, breast cancer cells T47D and metastatic cancer cells MDA-MB-231 was first 
subjected to Western blot analysis. It is known that cathepsin B presents in two forms, i.e. 
proenzyme and active form, with the molecular weight of  ~37 kDa and ~25 kDa, respectively, 
by SDS-PAGE.
167
 Incubated in activation buffer consisting of 5 mM DTT and 25 mM MES 
converts a portion of pro cathepsin B into the active enzyme.
167
 The Western blot results in 
Figure C.6a clearly show the presence of both pro and active forms of cathepsin B in WCE of all 
breast cells, with the content of the active form generally higher than that of the pro form. It 
needs to be noted that the band intensity among the four cell lysates in Figure C.6a varied due to 
different sample loading and immunoblotting conditions, as indicated by the control Western 
blot results of actin in these samples (see Figure C.1). In order to prove the electrochemical 
signal decay is indeed due to proteolysis from cathepsin B, cathepsin B-depleted lysate samples 
were used. Cathepsin B was precipitated out from the same amount of WCEs using cathepsin B 
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antibody. The pellets (the immunoprecipitated fraction) containing the concentrated and purified 
cathepsin B were then subjected to Western blot analyses all in one run.  Figure C.6b and Table 
C.1 illustrate that, with the same initial loading of 500 µg WCE, the total integrated pixel 
intensity of cathepsin B in the Western blot bands increased in cancer cell lysates. The linear 
relationship of the Western blot band intensity with the amount of enzyme was verified with 
experiments using purified cathepsin B (Figure C.2). After one round of IP, small but detectable 
amount of cathepsin B still present in the supernatant of the lysate (shown in 1X column of 
Figure C.6a). However, no obvious amount of cathepsin B was found in the supernatant after 2 
to 3 times of IP (shown in the 3X column of Figure C.6a), indicating a complete removal of 
cathespin B in the sample. 
 5.3 Electrochemical study of proteolysis of breast cancer cell lysates (MDA-
MB-231) 
 
Figure 5.1 The normalized proteolysis curves of (a) 7.28 µg·mL
-1
 MDA-MB-231 cell extract 
with cathepsin B partially removed by two times immunoprecipitation (2IP) (blue triangle), this 
sample spiked with ~13.3 nM (0.45 µg·mL
-1
) purified cathepsin B (green inverted triangle), and 
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7.28 µg·mL
-1
 MDA-MB-231 whole cell extract (pink dots); (b) 7.28 µg·mL
-1
 2IP MDA-MB-231 
cell extract spiked with ~38.0 nM (1.30 µg·mL
-1
) purified cathepsin B. All ACV measurements 
were carried out at f = 800 Hz and AC voltage amplitude V0 = 150 mV. 
The electrochemical detection of cathepsin B activity in the breast cancer cell followed 
the method in our previous study.
2
 The direct lysate of breast cancer cell MDA-MB-231 and that 
with cathepsin B removed by two rounds of IP (denoted as 2IP) have been studied. The cathepsin 
B specific tetrapeptide H2N-(CH2)4-CO-Leu-Arg-Phe-Gly-NH-CH2-Fc was immobilized on 
VACNF NEAs as the substrate for the enzymatic reaction. Twenty five µL of the activated lysate 
sample was added into the electrochemical cell containing 250 µL of 25 mM MES (pH 5.0) 
while ACV signal from the Fc-appended tetrapeptide was repeatedly recorded. In Figure 5.1a, 
the final total protein concentration of the lysate is 7.28 µg·mL
-1
. Adding both lysate samples 
caused kinetic exponential decay in the extracted electrochemical signal S. The fitted time 
constants are τ1 = 215 s for MDA-MB-231 cell lysate (pink dots) and τ2 = 533 s for the cathepsin 
B-removed lysate (blue triangle). Cathepsin B-removed lysate (by 2IP) showed 2.5 times slower 
kinetic decay rate compared to the direct lysate. In order to confirm that the difference of decay 
rate is indeed due to the removal of cathepsin B, 13.3 nM cathepsin B was spiked into the 7.28 
µg·mL
-1 
cathepsin B-removed MDA-MB-231 lysate (green inverted triangle). The decay time 
was shortened from τ2 = 533 s to τ3 = 352 s.  
According to Equation 4.6, the value of kcat/KM can be derived by:  
(kcat/KM)·([E0] + 13.3 nM) - (kcat/KM)·[E0] = 1/ τ3 – 1/ τ2 = 0.96 x 10
-3
 s
-1
,                   (5.1)                                                                                                                              
which gives kcat/KM  = 7.22 x 10
4
 M
-1
s
-1
. This value is slightly larger than our previous result, 
4.90 x 10
4
 M
-1
s
-1
 which derived from the purified cathepsin B.
2
 We can also obtain the difference 
of cathepsin B in direct and cathepsin B-removed MDA-MB-231 lysates as following:  
70 
                      (kcat/KM) ΔE0 = 1/ τ1 – 1/ τ2 = 2.77 x 10
-3
 s
-1
.                                           (5.2) 
Since kcat/KM equals to 7.22 x 10
4
 M
-1
s
-1
 according to above calculation, the difference of 
cathepsin B in 7.28 µg·mL
-1 
MDA-MB-231 lysate and cathepsin B-removed lysate, i.e. ΔE0, can 
be calculated as ~38 nM. To investigate whether our calculation is legitimate, we spiked 38 nM 
(1.30 µg·mL
-1
) cathepsin B into 7.28 µg·mL
-1 
cathepsin B-removed MDA-MB-231 lysate. A 
similar decay time τ4 = 207 s (versus τ1 = 215 s in 7.28 µg·mL
-1 
of original
 
MDA-MB-231 cell 
lysate) was obtained as shown in Figure 5.3b, validating that the higher proteolytic rate was 
indeed due to high cathepsin B concentration.  
In principle, the 2IP cell lysate should not cause any exponential decay in contrast to the 
significant decay in Figure 5.1a. In previous studies,
1-2
 we have demonstrated that the 
tetrapeptide H2N-(CH2)4-CO-Leu-Arg-Phe-Gly-NH-CH2-Fc can be selectively cleaved by 
cathepsin B but not legumain. However, the cell lysate contain many unknown proteases which 
could cleave the tetrapeptide at any possible sites. To identify a highly selective peptide remains 
a big challenge of today’s research. Our future studies will focus on screening the peptides with 
the optimum selectivity from a large library of peptide substrates. 
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Figure 5.2 The normalized proteolysis curves of (a) 2.43 µg·mL
-1
 (blue diamond), 7.28 µg·mL
-1
 
(pink dots) and 29.1 µg·mL
-1
 (black triangle) MDA-MB-231 whole cell extract. (b) Plot of –
dS/dt vs S during the proteolytic reaction by the cell extracts demonstrated in panel A. The slope 
is equal to the inverse of the exponential decay, i.e. 1/. All ACV measurements were carried out 
at f = 800 Hz and AC voltage amplitude V0 = 150 mV. 
The proteolysis of tetrapeptide H2N-(CH2)4-CO-Leu-Arg-Phe-Gly-NH-CH2-Fc by 
different concentrations of MDA-MB-231 cell lysates was also studied. As shown in Figure 5.2a, 
the decay rate increases with the increasing concentrations of MDA-MB-231 lysates. The decay 
time constants are 53 s, 215 s and 410 s for 29.1, 7.28 and 2.43 µg·mL
-1
 MDA-MB-231 cell 
lysates, respectively. According to Equation 4.6, (kcat/KM)·[E0] can be represented by 1/τ or the 
slope of Figure 5.2b (i.e., -dS/dt versus S). The values of (kcat/KM)·[E0] derived from the slope 
were 1.86 x 10
-2
, 4.60 x 10
-3
 and 2.42 x 10
-3
 s
-1
 with lysate concentration at 29.1, 7.28 and 2.43 
µg·mL
-1
, respectively. The quantity of (kcat/KM)·[E0] deviated from linear relationship at the low 
lysate concentration [E0] = 2.43 µg·mL
-1
, posing the low limit of lysate concentration for 
quantitative analysis. However, the results showed that this technique can reliably measure the 
protease above ~2.43 µg·mL
-1
. 
72 
 5.4 Specificity study by using cathepsin B inhibitor GC-373 
       
 
Figure 5.3 (a) The normalized proteolysis curves of 30.7 nM (0.89 µg·mL
-1
) purified 
recombinant cathepsin B after (1) normal activation procedure by incubation for 15 min in the 
activation buffer (5 mM DTT and 25 mM MES buffer, pH 4.0) (red dot), (2) with additional 30 
min incubation after the normal activation (dark yellow triangle), and (3) adding 0.6 µM 
inhibitor GC-373 during the 30 min additional incubation (blue diamond). (b) The normalized 
proteolysis curves of 7.28 µg·mL
-1 
MDA-MB-231 incubated for 30 min with (green dot) and 
without (pink dot) adding 0.6 µM inhibitor GC-373 after the normal 15 min activation 
procedure. 
To assess the specificity of the electrochemical detection of cathepsin B activity, an 
inhibitor GC-373 which inhibits the activity of cathepsin B was applied. The IC50 value of 9.67 
nM was first measured with the fluorescence assay (Figure C.4). The proteolysis of tetrapeptide 
H2N-(CH2)4-CO-Leu-Arg-Phe-Gly-NH-CH2-Fc by purified recombinant cathepsin B with and 
without inhibitor was then measured as shown in Figure 5.3a. Three sets of measurement were 
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done with 30.7 nM cathepsin B: (1) with normal 15 min activation in the activation buffer (5 mM 
DTT and 25 mM MES buffer, pH = 5.0); (2) with extra 30 min incubation following the normal 
activation; and (3) with 30 min incubation with added 0.6 µM GC-373 inhibitor following the 
normal activation.  Since the inhibitor requires 30 min incubation with the activated cathepsin B 
for it to take effects, experiment 2 is needed as the control. The decay time for the cathepsin B 
being activated for 15 min is 1287 s, giving (kcat/KM)·[E0] (= 1/τ) equals to 7.77 x 10
-4
 s
-1
. With 
further incubation for 30 min, the enzyme is more active, giving a smaller decay time of 397 s. 
After adding the GC-373 inhibitor, the decay time dramatically increases to 4,812 s. 
Accordingly, the cathepsin B activity (kcat/KM)·[E0] dropped by ~12 fold from 2.52 x 10
-3
 s
-1
 to 
2.08 x 10
-4
 s
-1
. The same trend was also found by using fluorescence method shown in Figure S5. 
The above results implied that inhibitor GC-373 is an efficient inhibitor for cathepsin B. 
Furthermore, Figure 5.3b showed that inhibitor GC-373 treated cancer cell lysate MDA-MB-231 
also exhibited 3.4 fold lower proteolysis activity compared to the untreated lysate, with 
(kcat/KM)·[E0] of  1.37 x 10
-3
 s
-1
 vs. 4.65 x 10
-3
 s
-1
 and the decay time constant of 729 s vs. 215 s. 
This result illustrated that cathepsin B was the major protease responsible to the cleavage of the 
tetrapeptide H2N-(CH2)4-CO-Leu-Arg-Phe-Gly-NH-CH2-Fc in the electrochemical 
measurements, but other proteases in cancer cell lysate MDA-MB-231 also made some 
contributions. 
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 5.5 Comparison of proteolysis kinetics of different breast cell lysates 
         
Figure 5.4 (a) The normalized proteolysis curves of 7.28 µg·mL
-1
 of HMEC cell extract (green 
diamond), MCF-10A cell extract (blue inverted triangle), T47D cell extract (cyan square) and 
MDA-MB-231 cell extract (pink diamond), respectively. (b) The plot of –dS/dt vs. S during the 
enzymatic reaction of the cell extracts in panel a.  
A major goal of today’s research is to develop methods that can quantitatively detect 
protease in complex samples and correlate the results with cancer formation. Toward this goal, 
one type of primary culture cells and three different breast cell lines were used to investigate 
whether the electrochemical detection of cathepsin B activity using VACNF NEAs could have 
biological significance. A solution of 25 µL of normal mammary cell HMEC lysate, non-
tumorigenic breast cell MCF-10A lysate, breast cancer cell T47D, or metastatic breast cell 
MDA-MB-231 lysates at total protein concentration of 7.28 µg·mL
-1 
was added into the 
electrochemical cell filled with 250 µL of 25 mM MES buffer (pH = 5.0). The decay time clearly 
varied among these different cell lysates (Figure 5.4a) giving τ = 497, 311, 248 and 215 s for 
7.28 µg·mL
-1 
of HMEC, MCF-10A, T47D, and MDA-MB-231, respectively. The values of 
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(kcat/KM)·[E0] derived from 1/τ or the slope of –dS/dt versus S are 2.00 x 10
-3
, 3.20 x 10
-3
, 4.02 x 
10
-3
 and 4.60 x 10
-3
 s
-1
 accordingly (Figure 5.4b).  
 
Figure 5.5 (a) Comparison of the (kcat/KM)·[E0] values derived from 7.28 µg·mL
-1
 HMEC, MCF-
10A, T47D and MDA-MB-231 cell extracts reacting with tetrapeptide H2N-(CH2)4-CO-Leu-Arg-
Phe-Gly-NH-CH2-Fc on VACNF NEAs. The error bars represent standard deviation from the 
mean from three measurements. (b) The normalized proteolysis curves of 7.28 µg·mL
-1
 HMEC 
cell extract spiked with 48.2 nM (1.63 µg·mL
-1
) purified cathepsin B. The AC measurements 
were carried out at f = 800 Hz and AC voltage amplitude V0 = 150 mV. 
Most of the early stage mammary tumors are ER-positive and many patients could 
respond to anti-estrogen or endocrine therapy
172-175
 and later stage breast cancers become 
resistant to endocrine therapy and are more malignant, aggressive, invasive and metastatic
176-180
. 
HMEC is derived from normal mammary tissue, and MCF-10A is a non-tumorigenic cell line, 
while T47D and MDA-MB-231 cell lines are derived from breast cancer patients. MDA-MB-231 
has been shown to be estrogen receptor (ER)-negative, indicating a more aggressive form of 
breast cancer. Excitingly, our electrochemical results showed that the values of (kcat/KM)·[E0] (= 
1/τ) significantly increased in the cancer cell lysates. Comparison of the values of (kcat/KM)·[E0] 
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of different breast cell lysates at concentration of 7.28 µg·mL
-1
 in bar graph is shown in Figure 
5.5a. Triplicated experiments were carried out for each cell lysates. The statistical values of 
(kcat/KM)·[E0] are (2.13 ± 0.73) x 10
-3
, (3.62 ± 0.44) x 10
-3
, (4.39 ± 0.34) x 10
-3
 and (5.61 ± 1.09) 
x 10
-3
 s
-1
 for HMEC, MCF-10A, T47D and MDA-MB-231 cell lysates, respectively. This trend 
is correlated well with our Western blot results (Figure 5.1b).  
In order to estimate the overexpressed amount of cathepsin B in cancer cell lysates 
compared to the normal cells, an experiment was done by spiking certain amount of cathepsin B 
into HMEC lysate solution. According to Equation 4.6, the difference of cathepsin B in HMEC 
and MDA-MB-231 cell lysates at concentration of 7.28 µg·mL
-1
 can be derived as:  
   (kcat/KM)·ΔE0 = 5.61 x 10
-3
 – 2.13 x 10-3 = 3.48 x 10-3 s-1.                                         (5.3) 
Assuming that kcat/KM equals to 7.22 x 10
4
 M
-1
s
-1 as obtained earlier, ΔE0 equals to 48.2 
nM. This implied that 7.28 µg·mL
-1 
HMEC spiked with 48.2 nM purified cathepsin B should be 
equivalent to 7.28 µg·mL
-1 
MDA-MB-231. The kinetic curves after spiking 48.2 nM purified 
cathepsin B into 7.28 µg·mL
-1 
HMEC solution indeed showed a decay time constant comparable 
to the same concentration of MDA-MB-231 cell lysate, as shown in Figure 5.5b. The statistic 
value of the decay time from three repeating measurements was (255 ± 30) s, giving a 
(kcat/KM)·[E0] value of (3.97 ± 0.50) x 10
-3
 s
-1
 falling between (3.62 ± 0.44) x 10
-3
 s
-1
 for MCF-
10A and (4.39 ± 0.34) x 10
-3
 s
-1 
for MDA-MB-231. The higher proteolysis rate of cancer cell 
lysate is indeed due to elevated cathepsin B activity. 
Proteolysis by breast cell lysates has also been studied with a commercial fluorescence 
assay using 0.05 mg·mL
-1 
lysate of HMEC, MCF-10A, T47D and MDA-MB-231. Even though 
this method works well in measuring proteolysis of purified recombinant cathepsin B and was 
used as a validation technique in our previous studies,
1-2
 the results were quite diverging and 
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unreliable in measuring cell lysates. Despite that the lysate concentration was about 10 times of 
that in electrochemical experiments, none of the kinetic curves except T47D lysate showed clear 
exponential increase in fluorescence intensity due to proteolytic cleavage of the AMC group 
from the peptide substrate. The fluorescence intensity was in general 10 to 100 times lower than 
the measurements using purified cathepsin B solutions at comparable or even lower 
concentrations. The measurements in MCF-10A and MDA-MB-231 cell lysates only showed 
noisy uncharacteristic fluctuations. None of these measurements were able to be used for 
quantitative analysis. It is noted that the fluorescence assay can only use a rather simple substrate 
Z-Leu-Arg-AMC where the signal moiety AMC has to be attached to the cleavage site Arg at the 
end of the peptide due to its fluorescence mechanism. The lack of specificity and strong 
interference likely limited this commercial fluorescence assay from measuring the proteolytic 
kinetics of the complex cell lysates. Further study for a better understanding of this phenomenon 
is still in progress. 
 5.6 Discussion 
In this study, we have shown that cathepsin B exits as both pro and active forms in the 
whole cell extract of normal breast cells (HMEC), non-tumorigenic breast cells (MCF-10A) and 
breast cancer cells (T47D and MDA-MB-231). Our results also demonstrated that the total 
integrated pixel intensity from the Western blot bands, thus the amount of cathepsin B, increased 
for the cancer cell lysates. However, the commercial fluorescence assay is not suitable to study 
the proteolytic kinetics of the cathepsin B in the cell lysates. In contrast, electrochemical method 
applied on VACNF NEAs has shown great potential and advantage in quantitative study the 
complex cell lysates. We have shown that ACV measurements is a reliable tool to derive the 
value of (kcat/KM)·[E0] from the cancer cell lysate solutions. The spiking experiments results 
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confirmed that the elevated proteolytic rate is due to the cathepsin B. Well-separated protruding 
VACNF tips immobilized with the peptide substrate likely facilitate the protease to reach and 
cleave the specific site of the peptides. The results from inhibitor experiment illustrated that 
proteases other than cathepsin B in the cancer cell lysate also contributed to the cleavage of the 
tetrapeptide substrate. We also found that the protease activity (i.e., the value of (kcat/KM)·[E0]) 
increased for the cancer cells, consistent with Western blot results. The value of (kcat/KM)·[E0] is 
the highest for metastatic cancer cell MDA-MB-231, then followed by cancer cell T47D and 
non-tumorigenic cell MCF-10A. Normal cell lysate HMEC showed the smallest value of 
(kcat/KM)·[E0], thus lowest protease activity. To our knowledge, this is the first report to use 
simple electrochemical method to quantify the protease activities in complex cell lysates and 
identify the cancer formation. Integrated in the multiplex system, this electrochemical biosensor 
can be potentially used for improving cancer diagnosis, treatment monitoring, and drug (inhibitor) 
screening.  
Although this electrochemical technique is viable for detecting cathepsin B activity in 
tissue or cell lysates, it would have broader impact if it can profile protease in serum or urine 
samples. According to Karel Kotaska et al.’s bladder cancer study, the concentration of cathepsin 
B in serum is in the range of 27-126 µg·L
-1
 and that in urine is in the range of 0-2.54 µg·L
-1
.
163
 
The lowest concentration of purified cathepsin B by using ACV on VACNF NEA in our 
previous study is ~450 µg·L
-1 
(13.3 nM), about 4-20 times of the concentration of cathepsin B in 
serum and >200 times more in urine.
2
 In order to effectively detect the cathepsin B in serum or 
urine samples, the detection limit of our electrochemical method needs to be further improved. 
One of the approaches is to use e-beam patterned VACNF NEAs which has exhibited enhanced 
performance in our previous study due to more uniform SiO2 encapsulation and smaller 
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background from nonspecifically adsorbed Fc-peptide.
2
 At the same time, the serum or urine 
samples can also be concentrated in order to effectively measure cathepsin B activity by using 
electrochemical method. It is noteworthy that cell culture (as used in this study) is the key to new 
drug discovery and screening analysis. Not only the 2D cell culture allows rapid and cost-
effective approach, it also provides a simple and control environment to design a new 
technology. However, the 2D cell culture has its limitation due to the flat environment and lack 
of the complexity of cell network in biological system. In the previous study
2
, we have 
demonstrated that this electrochemical technique also works nicely in the complex tissue lysates. 
The next logical step is to detect the level of cathepsin B activity in clinical tumor samples.  
The absolute concentration [E0] of cathepsin B also needs further study. From the 
difference in the proteolytic rates between the original WCE and 2IP
 
MDA-MB-231 lysates, the 
concentration of removed cathepsin B was calculated to be ~38 nM according to Equation 5.2. 
The mass percentage of cathepsin B in MDA-MB-231 cell extract can be calculated as ~18% 
(1.3 µg·mL
-1
 cathepsin B in 7.28 µg·mL
-1
 total cell protein). However, according to the Western 
blot data (Table C.1) and the calibration curve (Figure C.2), the approximate percentage of 
cathepsin B in MDA-MB-231 is only ~0.13 %. Besides loss of the some cathepsin B during 
Western blot procedures, there are two other possibilities at this stage to explain such a large 
discrepancy. First, the kcat/KM value of the cathepsin B in the cell lysate may be much larger than 
that of the purified recombinant cathepsin B. Thus more recombinant cathepsin B was needed in 
the spiking experiments, leading to overestimation of cathepsin B quantities. The large variation 
in kcat/KM value of cathepsin B is quite common in literature. For example, it varies from ~2 x 
10
3
 M
-1
s
-1 150
 to 7 x 10
6
 M
-1
s
-1 181
 depending on the source of cathepsin B and the nature of the 
peptide substrates. Second, the complex matrix of the cell lysate may have strong interference to 
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suppress the activity of the spiked recombinant cathepsin B, making its real kcat/KM value much 
lower than what we measured in simple buffer solutions in previous studies, thus more cathepsin 
B was needed to reach the same effects. This is consistent with the known network interaction 
with other enzymes in complex samples. 
 5.7 Conclusions 
In summary, this work demonstrated two critical features toward rapid protease profiling 
using an electrochemical method based on nanoelectrode arrays fabricated with vertically 
aligned carbon nanofibers. First, continuously repeated ACV measurement of Fc-tetrapeptide 
attached to VACNF NEAs has been proved to be a reliable tool to measure the proteolytic 
kinetics and quantify the protease activity in complex breast cell lysates. Second, the activity of 
cathepsin B measured by this electrochemical method was found to increase from normal to 
cancer cell lysates. The clear inhibitor effects indicated that this method may be used as an 
effective technique for inhibitor screening in the complex biological samples. This study 
demonstrates the feasibility for future protease profiling using a library of peptide substrates 
specific to interested proteases on independently addressed NEAs. It could be potentially 
developed into a portable multiplex electronic system for cancer diagnosis, assessment of 
treatment efficacy, and drug screening. 
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Chapter 6 - Ultrasensitive blood-borne pathogen biosensor based on 
chemiluminescence (CL) method 
Reproduced in part by permission of Royal Society of Chemistry.  
Published as Syed, L. U.; Swisher, L. Z.; Huff, H.; Rochford, C.; Wang, C.; Liu, J.; Wu, 
J.; Richter, M.; Balivada, S.; Troyer, D.; Li, J. Analyst 2013, 138, 5600-5609. 
 6.1 Introduction 
CL is a process in which visible light is emitted as a result of chemical reactions. CL is a 
much more sensitive and convenient analytical technique than commonly used FL methods due 
to high quantum yield, no need for exciting light sources, and low background.
182
 It has been 
widely utilized for forensic investigations by spraying luminol (5-amino-2,3-dihydro-1,4-
phthalazine-dione) and hydrogen peroxide at crime scene to identify dried blood stains.
183
 Here, 
we report a study to improve luminol based CL by covalently attaching luminol molecules onto 
GNPs through a monolayer of carboxylic acid terminated alkane thiols. GNPs can serve as high-
surface-area nanocarriers, making manipulation and binding of a large amount of luminol 
moieties easier. Detection of the CL signal generated by luminol on GNPs is expected to be 
much more sensitive than colorimetric measurements based on GNP aggregation that are used in 
many analytical applications. 
GNPs have gained a considerable attention in the past few decades due to their 
unparalleled optical, electronic, physical, and chemical properties.
184-186
 Ease of surface 
modification of GNPs with alkane thiol molecules and further covalent linking with other 
chemical and biological moieties make GNPs an attractive choice for sensor applications.
187-190
 
In addition, GNPs present strong size-dependent SPR, which significantly enhances the 
sensitivity of colorimetric or optical absorption detection of GNP based sensors.
88, 191-196
 Here, 
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we demonstrate that GNPs can be used as convenient nanocarriers for luminol molecules, 
generating strong CL. 
Luminol belongs to the family of heterocyclic hydrazide compounds, and is by far one of 
the most popular agents for CL applications.
196-199
 Under the proper reaction conditions, luminol 
can generate strong blue-colored luminescence peaking at ~425 nm wavelength. The concept of 
light production by luminol catalyzed with Fe
3+
 ions released from red blood cells is the basis of 
forensic and hospital analysis of blood contamination.
183, 200-201
 In many experiments to study 
luminol CL, ferricyanide ions [Fe(CN)6]
3-
 were used as the catalyst due to the higher chemical 
stability. When GNPs are involved, however, it is not conclusive how the GNPs affect the CL 
signal,
202-203
 particularly since the SPR of GNPs strongly depends on their size and shape. Some 
studies using bare GNPs directly mixed with CL reagents reported that the CL signal was 
inhibited due to quenching by GNPs when their diameters were less than 5 nm, but was 
enhanced, possibly due to catalytic effects, when the GNP diameters were ~25 to 38 nm.
202-203
 
However, in another study using luminol molecules covalently attached to 30 nm-diameter 
GNPs, CL was found to be reduced by about five fold comparing to in bulk solutions.
204
 
In general, electron transfer might facilitate catalytic effects to enhance CL while energy 
transfer to GNPs is sure to cause nonradiative deactivation (quenching) of chemically excited 
luminol products. The effect of GNPs to luminol CL was found to be minimal when the diameter 
was in the range of 5 to 10 nm.
202-203
 To avoid the complication, we chose to use 10 nm-diameter 
GNPs in this study, where GNPs mainly serve as nano-carriers for manipulating and placing of 
large amount of luminol molecules in highly reduced volumes (or areas) by taking the advantage 
of the large surface-to-volume ratio of GNPs. In this study, the surface of GNPs is protected with 
a close-packed self-assembled monolayer of a long-chain thiol linker, mercaptoundecanoic acid 
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(MUA), to minimize both electron transfer and energy transfer between luminol and the GNP. 
This allowed us to assess the controversial results in previous studies
196, 202-204
 on whether the 
surface-functionalized luminol can generate enhanced CL than in bulk solutions. Using this 
design, we have observed largely enhanced CL from luminol-labeled GNPs and have found that 
the CL intensity can be detected while the number of GNPs was varied by 8 orders of magnitude.  
               
Figure 6.1 (a) Schematic illustration of viral nucleic acid biosensor based on CL detection by 
optical fibers. (b) Hybridization of HA target on the nanoparticles and HA probe on the optical 
fiber.  
The study described here is aiming to design a new generation of chemiluminescent 
nanoparticle-based bio-detectors for blood-borne pathogens, such as H1N1. We expect to 
functionalize probe 1 on the optical fibers and after inserting the optical fibers into the fluids 
containing H1N1 viral nucleic acid (target), the probe 1 will hybridize with the target. Then, the 
hybridization of probe 2 with target will be performed. Probe 2 and luminol molecules are co-
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immobilized on the surface of the carrier nanoparticles (Figure 6.1a). The concentration of the 
viral nucleic acid will be determined from the intensity of the chemiluminescence due to luminol 
molecules. The developed assay will be incorporated into a portable device for routine assays in 
hospitals or for large-scale screening of human populations to curb the rapid spread of the H1N1 
virus and other viral or bacterial pathogens. In order to reach this goal, we start from preparing 
nanoparticles which are co-functionalized with both H1N1 nucleic acid fragment, such as 
influenza hemagglutinin sequence (HA target), and luminol and also functionalizing optical 
fibers with HA complimentary nucleic acid (HA probe) (Figure 6.1b). The hybridization of HA 
target and HA probe is investigated by fluorescence microscope and SEM. The CL performance 
using luminol-labeled latex beads (30 nm diameter) and luminol-labeled GNPs (10 nm diameter) 
are assessed and compared.  
 6.2 Experimental details 
  6.2.1 Materials and reagents 
Citrate protected GNPs (8.0-12.0 nm in diameter) were purchased from Sigma Aldrich 
(Saint Louis, MO, USA) and BB International (UK). Carboxylate-modified latex beads in 30 nm 
diameter, mercaptoundecanoic acid (MUA), APTES and succinic anhydride were purchased 
from Sigma Aldrich (Saint Louis, MO, USA). Luminol (LUM), EDC, sulfo-NHS, Tween 20, 
potassium ferricyanide (K3Fe(CN)6), phosphate buffer saline (PBS), sodium hydroxide (NaOH), 
hydrogen peroxide (H2O2), dimethylformamide (DMF), ammonia hydroxide (NH4OH) and 
microscope slides were obtained from Fisher Scientific (Pittsburgh, PA, USA). All chemicals 
used in this study were analytical grade. DI water with a resistivity of 18.2 MΩ-cm from a 
portable filtration system (Barnstead EASYpure II RF/UV, Model D7035, Thermo Scientific, 
Asheville, NC, USA) was used in all the experiments. 5’Cy5-
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GGGGGCAATCAGTTTCTGGATGTGCTC-3’-C7-NH2 (HA probe) and H2N-C7-3’-
CCCCCGTTAGTCAAAGACCTACACGAG-5’-Cy3 (HA target) were ordered from Eurofins 
Genomics (Huntsville, AL, USA). Polyethylene jacketed polymethyl-methacrylate (PMMA) 
optical fibers were purchased from Industrial Fiber Optics, Inc. (Tempe, AZ, USA). 
 6.2.2 Characterization of instruments 
UV-visible absorption spectra were recorded using Beckman DU640 spectrophotometer 
in a 360 μL microcuvette with an optical path length of 10.0 mm. Infrared spectroscopy (IR) was 
performed on a Nicolet 380 FT-IR spectrophotometer with neat solid samples using an 
attenuated total reflectance (ATR) accessory. Fluorescence images of latex beads immobilized 
glass slide were taken by using an upright fluorescence optical microscope (Axioskop 2 FS plus; 
Carl Zeiss). The immobilization of latex beads on the optical fibers were investigated by using 
field-emission scanning electron microscopy (FESEM) (Leo 1550, Zeiss). 
6.2.3 Modification of nanoparticles with luminol and/or viral nucleic acid 
6.2.3.1 Modification of gold nanoparticles (GNPs) with luminol 
The scheme to functionalize the GNPs with luminol is illustrated in Figure 6.2. The initial 
step was to exchange the citrate groups on the surface of GNPs with the MUA ligands under the 
protection of the nonionic surfactant Tween-20. Typically, 2 mL of citrate-protected GNP stock 
solution (5.99 x 10
11
 particles/mL) was transferred to a clean, dry test tube with a screw-cap 
followed by addition of 2 mL of 1X PBS with 0.2 mg/mL Tween-20 buffer (the same buffer 
composition was used for all following functionalization steps in this work). The mixed solution 
was incubated at room temperature for 30 min before 2 mL of 3.0 mM MUA solution (in 1:3 v/v 
ratio of ethanol/DI water mixture) was added. The solution was further incubated overnight at 
room temperature with gentle shaking. The mixture was centrifuged at 14,500 rpm (~14,100 G) 
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for 20 min to pellet the MUA-modified GNPs (GNP-MUA). The supernatant was discarded and 
the pellet was re-suspended in the buffer. The pellet was washed three times before being 
suspended in the buffer. MUA-modified GNPs (200 µL) then reacted with 100 µL of freshly 
prepared aqueous solution containing 50 mM  EDC and 50 mM sulfo-NHS for 15 min. This 
mixture was then combined with 100 µL of 50 mM LUM solution (a few drops of 0.4 M NaOH 
were added to increase the solubility of LUM in DI water) and incubated at room temperature for 
2 h. Finally, the LUM-modified GNPs (GNP-MUA-LUM) were washed 3 times with buffer and 
finally suspended in the buffer solution to obtain a final concentration of ~1x10
12
 GNP/ml. The 
GNP concentrations before and after functionalization were calculated using the peak absorbance 
at 516 nm, in good agreement with the value for stock GNPs provided by the vendor. As shown 
in figure 6.2, by varying the concentration of luminol-labeled GNPs and fixing the concentration 
other CL reagents, the system can be developed into DNA biosensors through co-
functionalization of target DNA and luminol on GNPs (scheme I). If varying the concentration of 
Fe
3+
, the system can be developed into a biosensor to detect Fe
3+
-carrying analytes such as red 
blood cells (scheme II). The study described here focuses on the application based on scheme I.  
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Figure 6.2 Schematic of the two-step covalent modification of GNPs with LUM by ligand 
exchange to replace citrate with MUA and amide linkage of the –COOH group in MUA with –
NH2 group in LUM. Two schemes to implement luminol-labeled GNPs (compound A) for 
chemical analyses are illustrated: Scheme I - to detect the amount of A by supplying sufficient 
Fe
3+
 catalyst and other reagents (H2O2 and NaOH); Scheme II - to detect Fe
3+
-carrying analytes 
(such as red blood cells) which can catalyze the CL reaction in presence of sufficient amount of 
A and other reagents (H2O2 and NaOH).  
6.2.3.2 Modification of latex beads with luminol and viral nucleic acid (Latex beads-HA 
probe/LUM) 
Incubate 100 µL latex beads solution (4.75 x 10
10
/mL) with 200 µL 4 mM EDC, sulfo-
NHS and 100 µL 1 µM NH2-(HA target)-Cy3 in 1 x PBS buffer at 37 °C for 2 hr; then add 100 
µL 10 mM luminol and 100 µL 2 mM EDC, sulfo-NHS solution into above HA target 
functionalized latex beads solution (latex beads-HA target) and incubate at 37 °C for another 2 
hr. Wash the HA target and luminol co-functionalized latex beads solution (latex beads-HA 
target/LUM) four times in 50 mM tris-HCl buffer by centrifuging at 14.1 x 1000 rcf speed for 1 
hr each time. Re-suspend the latex beads-HA target/LUM pellet into 3 x SSC buffer after the last 
centrifuging.  
 6.2.4 Immobilization of latex beads on glass slide and PMMA optical fibers 
The scheme to immobilize DNA probe on the glass surface was shown in figure 6.3. The 
glass slide was first treated by Piranha solution (concentrated H2SO4: 30% H2O2 = 3:1) for 20 
min to generate hydroxyl groups on the surface, and then followed by DI H2O and ethanol 
washing.
205
 Dip the fiber in 1% NH4OH solution at 80 °C for 1 hr to make the surface 
hydrophilic. Then, the fiber was emerged in 2% APTES ethanol solution for 2 hr in order to form 
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amine groups on the surface. The fiber was then kept in 1M succinic anhydride dissolved in dry 
DMF for overnight. The fiber was now terminated by –COOH and ready for DNA 
immobilization. Immerse –COOH terminated optical fiber tip in the solution of 5 – 20 µM HA 
probe with 10 mM EDC and sulfo-NHS in 1 x PBS buffer. Then, incubate the fiber with DNA 
solution in a humidity chamber at 37 °C for 2 hr. HA probe immobilized optical probe was then 
ready to hybridize with HA target-functionalized latex beads (latex beads-HA target/LUM). For 
immobilization of latex beads on the PMMA optical fiber, 3M H2SO4 solution or oxygen plasma 
etching can be used to generate –COOH groups on the surface. 
 
Figure 6.3 Schematic of the immobilization of DNA probe on the glass surface. (Provided by 
Lateef U. Syed) 
Before immobilization of latex beads on the HA probe functionalized optical fiber or 
glass slide, blocking steps were followed in order to minimize the non-specific binding. Rinse 
the HA probe-functionalized optical fiber tip or glass slide by 1 x PBS buffer for three times, and 
then incubate the fiber in 5 mM ethanol amine solution with 10 mM EDC, sulfo-NHS at room 
temperature for 1 hr. Finally, incubate the optical fiber or glass slide with latex beads-HA 
target/LUM solution in 3 x SSC buffer in the humidity chamber at 37 °C for 2 hr. By this means, 
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the latex beads were immobilized on the glass slide or optical fiber tip surface through double 
strand DNA chain.  
 6.2.5 CL measurements using commercial luminometer in 96 well plate 
CL experiments were carried out with a GloMax Multi+ system (Promega Corporation, 
CA, USA). The GloMax Multi+ system uses a photomultiplier tube (PMT) detector covering 350 
to 650 nm for single-channel measurements of the kinetic CL emission from individual wells in a 
standard round bottom white polystyrene 96-well plate with a volume of ~300 L per well (~6.5 
mm in dia and ~11 mm in depth). A ~9.0 mm diameter optical mask was placed in front of the 
PMT detector assembly to cut off the background from other wells while allowing only the light 
from the selected well to be measured. In the experiments, 25 µL of 0.10 M NaOH, 25 µL of 
1.41 M H2O2 and 25 µL of 1.0 mM K3Fe(CN)6 solution were preloaded in a well. Then 25 µL of 
luminol solution with varied concentration (~10
-14
 to 10
-5
 M) was added by a capillary injector at 
a rate of 200 µL/sec into the well to initialize the CL reaction. The CL signal was recorded 
continuously for ~8 min immediately following the injection. 
 6.3 Results and discussion 
 6.3.1 GNPs characterization 
In regard of GNP characterization using TEM, UV-visible and FT-IR spectrum, please 
refer to Lateef U. Syed’s dissertation 2012 and reference 3 for details. In short, strong absorption 
peaks were observed for all GNP samples at ~520 nm in the UV-visible absorption spectra. For 
the GNP-MUA-LUM, an additional small peak at 350 nm was observed, corresponding to the 
absorption peak of luminol. Clearly, the size of GNPs remained the same as they went through 
the ligand exchange and luminol functionalization processes. 
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For the GNP-MUA, the characteristic IR absorption peaks can be clearly seen at 2919 
and 2849 cm
-1
, which can be ascribed to the vibrational stretches of –CH2– functional groups in 
the MUA chain.
206
 The peak corresponding to the C=O stretch in the terminal carboxylic acid 
group in GNP-MUA was shifted from ~1700 cm
-1
 to ~1550 to 1650 cm
-1
 indicating that the 
carboxylic acid group was in the ionized form as carboxylate salts.
207
 This is consistent with the 
fact that the pH value of the suspension solution was ~7, above the pKa of the –COOH group. 
For the GNP-MUA-LUM, these IR bands split into three bands between ~1541 to 1730 cm
-1
, 
consistent with the formation of amide bonds between the –COOH group in MUA and the –NH2 
group in luminol.
208
 Also, a peak at 1396 cm
-1
 corresponding to the bending of C-H bond in the 
long alkane chain –(CH2)n– can be seen in GNP-MUA and GNP-MUA-LUM. The peaks 
corresponding to the C-H stretch of the alkane chain were observed at 2919 and 2849 cm
-1
 for 
GNP-MUA and at 2913 and 2864 cm
-1
 for GNP-MUA-LUM, confirming that the MUA 
monolayer was intact after LUM functionalization. The N-H stretch mode of luminol, which is 
expected to be at 3,300 to 3,500 cm
-1
, however, was buried under the strong and broad 
background absorption peak. The FTIR spectra clearly confirmed that the ligand exchange to 
replace citrate with MUA and functionalization of LUM to MUA were successful following the 
schemes shown in Figure 6.2.  
 6.3.2 Latex beads immobilization on glass slide and PMMA optical fibers 
6.3.2.1 Investigation of immobilization using fluorescence microscope 
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Figure 6.4 Fluorescence microscopy images of latex beads immobilized glass slide using (a) 
Cy5 filter with λex = 625-655 nm, λem = 665-715 nm; (b) Cy3 filter with λex = 540-552 nm, λem = 
575-640 nm and (c) filter with λex = 475-495 nm, λem = 515-565 nm in 4x magnification (Insert 
image: 50x magnification).  
Fluorescence microscopy images of latex beads-immobilized glass slide through HA 
probe and HA target hybridization using different filters was shown in figure 6.4. Filter was 
chosen according to the excitation and emission wavelengths of Cy5 dye on HA probe, Cy3 dye 
on HA target and the dye molecules on latex beads. The excitation and emission wavelengths of 
all the dyes were summarized in table 6.1 (the values were provided by the vendor). Around 100 
μL solution of 10 μM NH2-(HA probe)-Cy3, EDC and sulfo-NHS mixture was spread on the 
surface of –COOH terminated glass slide and incubated in the humidity chamber at 37 °C for 2 
hr. Thus, HA probe-Cy3 was immobilized on the glass slide through amide bond. Then, around 2 
μL of latex beads-HA target/LUM solution (4.75 x 1010/mL) was pinned on the surface of the 
HA probe-immobilized glass slide and kept in the humidity chamber at 37 °C overnight. After 
rinsing glass slide by 1 x PBS buffer and DI H2O thoroughly, the area where the solution of latex 
beads-HA target/LUM was pinned on clearly showed fluorescence using different filters (figure 
6.4). This result implied that latex beads were successfully immobilized on the glass slide surface 
through DNA hybridization.  
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Table 6.1 The excitation (λex) and emission wavelength (λem) of different dye molecules.  
Dye λex (nm) λem (nm) 
Cy5 650 670 
Cy3 550 510 
Dye on Latex beads 470 505 
 
6.3.2.2 Investigation of immobilization using SEM 
 
Figure 6.5 SEM images of latex beads immobilized on (a) & (b) side wall (clad) and (c) tip of 
the optical fiber core. 
The optical fiber consisted of polyethylene black jacket, the clad which is made of 
fluorinated polymer and PMMA optical fiber core. The core diameter is 1.84 – 2.08 mm. The 
refractive index of core is 1.49. The immobilization of latex beads on the surface of PMMA 
optical fiber core was investigated by using SEM. Figure 6.5 (a) and (b) showed the clad of 
optical fiber core with latex beads attached. The pits on the clad surface might be due to the 
treatment using 3M H2SO4. In addition, the density of latex beads on the clad surface was varied 
greatly, which may be caused by non-uniformity of the hydroxyl functional groups generated by 
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the acid treatment (figure 6.5a). However, 30-nm-diameter latex beads are distributed on the clad 
surface without aggregation. Figure 6.5c shows the tip of optical fiber core functionalized with 
latex beads. The density of the latex beads on the core surface was extremely low compared to 
the clad area. Due to the photons traveling through the tip of the fiber core and blocked by the 
clad, the density of latex beads on the surface of optical fiber tip needs to be greatly improved. 
 6.3.3 CL assessment 
The mechanism of light production by luminol has been extensively explored.
201, 209-211
 
The CL reaction of luminol generally utilizes Fe
3+
 as the catalyst and requires two equivalents of 
base to deprotonate the -NH-NH- group, leaving a negative charge that then undergoes resonance 
to form an enolate ion.
201
 Then a cyclic addition reaction of the oxygen (provided by H2O2) at the 
two carbonyl carbons takes place (with Fe
3+
 catalyzing the breakdown of peroxide into oxygen 
and water), leading to the expulsion of N2 in the gaseous form. This step leads to the formation 
of 3-aminophthalate (an excited form of luminol) and light emission peaking at a wavelength of 
425 nm while electrons return to the ground state.
201, 211
 In general, CL of luminol follows a flash 
mechanism in which CL occurs immediately and then decays at a time constant of tens of 
seconds.
211
  
94 
                               
Figure 6.6 Chemiluminescence measurement of GNP-MUA-LUM solutions at a series of 
concentrations as it was diluted across 8 orders of magnitude. In these experiments, 25 µL of 
0.10 M NaOH, 25 µL of 1.41 M H2O2 and 25 µL of GNP-MUA-LUM solution (containing 
varying number of GNPs from 1.82 x 10
10 
to 1.82 x 10
2
) were added in a 96-well plate and 
loaded in the Promega GloMax-Multi+ microplate reader. Then 25 µL of 1.0 mM K3Fe(CN)6 
solution was added into the mixture with a micro-injector to start the reaction and the 
chemiluminescence signal was recorded immediately. 
Figure 6.6 shows the kinetic CL curves of GNP-MUA-LUM in a 96-well plate with the 
number of GNPs in the wells varied by 8 orders of magnitude from 1.82 x 10
10
 to 1.82 x 10
2
 per 
well.  The number of GNPs instead of GNP concentration was used for ease of comparison with 
(
a) 
(
b) 
(
c) 
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the data in later sections of this study, but can be easily converted to concentration since the total 
volume in these experiments was fixed at 100 μL in each well. The light intensity (in relative 
light units, RLU) clearly followed an exponential decay.  
       
Figure 6.7 (a) The fitting of a representative kinetic chemiluminescence curve of GNP-MUA-
LUM solutions recorded with GloMax Multi+ system. In this set of data, 1.82 x 10
7
 GNP-MUA-
LUM nanoparticles was used. The curve fits nicely with an exponential decay over a linear 
background. The decay time constant is 35 s. (b) The calibration curve using integrated CL 
signal (the initial intensity a multiplied by the decay time constant ) instead of I in the vertical 
axis. The slopes of the two linear curves are 0.90 (at high N) and 0.038 (at low N), nearly the 
same as those using I. 
Figure 6.7 shows a representative kinetic CL curve measured with 1.82 x 10
7
 GNP-
MUA-LUM nanoparticles, giving a decay time constant of about 35 s. At other concentrations, it 
varied between ~35 and ~61 s. For ease of comparison, the difference of CL signal (ΔI) between 
the first point and the last point on a CL kinetic curve (see Figure 6.6a) was used as the 
background-corrected CL signal. 
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Figure 6.8 Calibration curves of the background-subtracted chemiluminescence signal I (as 
shown in Figure 6.6). (a) Plot vs. the number of GNP-MUA-LUM nanoparticles in the 96-well 
plate, and (b) Plot vs. the equivalent luminol concentration from the GNP-MUA-LUM 
nanoparticles in the mixed solutions (red filled squares) in comparison with the bulk luminol 
concentration in the mixed solutions (black filled circles). The error bars of the data with bulk 
luminol are standard deviations calculated from three measurements at each condition. 
Figure 6.8 summarizes the results from Figure 6.6 into calibration curves to illustrate CL 
for analytical applications under Scheme I. The CL signal can be observed clearly above that of 
the blank control sample as the quantity of the GNP-MUA-LUM was varied by 8 orders of 
magnitude, down to 1.82 x 10
2
 nanoparticles. Interestingly, the value of ΔI vs. number of GNPs 
(N) showed two distinct linear curves on the log-log scale. They can be fitted with the following 
functions: 
,1.82x10  Nfor    ,76.2log86.0)log( 6 NI     (6.1) 
and  .1.82x10  to1.82x10  Nfor    ,23.2log035.0)log(
52 NI   (6.2) 
At the low concentration limit, the slope is substantially less than 1 that is expected for a 
direct linear relationship. It is likely that the CL reaction was limited by slow diffusion or other 
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factors rather than by thermodynamic equilibrium. Nevertheless, the ΔI clearly increased with N. 
In the control experiments using deionized water to replace GNP solutions, the mean value of 
log(ΔIblank) is 1.87 and the standard deviation σlog(ΔI) is 0.015. Accordingly, the signal detection 
limit is log(ΔI)DL = log(ΔIblank) + 3σlog(ΔI) = 1.92. This means that even the lowest GNP-MUA-
LUM concentration in Figure 6.6 (with N = 1.82 x 10
2
) is detectable in principle. However, the 
small slope makes the precise quantification at very low GNP-MUA-LUM concentrations 
difficult. Since our goal in this work is to develop a robust analytical technique, the cross point 
of the two linear curves in Figure 6.8a is defined as the detection limit instead, which gives 1.1 x 
10
6
 GNP-MUA-LUM nanoparticles per well (corresponding to 1.8 x 10
-14
 M GNP). The 
calibration curve using integrated CL intensities extracted by the curve fitting to the kinetic data 
(as shown in Figure 6.7b) showed nearly the same results. 
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Figure 6.9 The kinetic CL measurements with bulk aqueous luminol solution at varied 
concentrations. The experimental conditions were identical with those in Figure 6.6 except the 
GNP-MUA-LUM solutions being replaced with bulk luminol solutions. About 25 µL of 0.10 M 
NaOH, 25 µL of 1.41 M H2O2 and 25 µL of 1.0 mM K3Fe(CN)6 solution were preloaded in a 96-
well plate. Then 25 µL of aqueous luminol solution with varied concentration (1.0 x 10
-14
 to 1.0 
x 10
-5
 M) was added by the micro-injector to initialize the CL reaction.   
The bulk aqueous solution of free luminol (Figure 6.9) presented a similar CL behavior. 
The background-subtracted signal ΔI vs. the luminol concentration showed two straight lines 
very similar to that of GNP-MUA-LUM in Figure 6.8a. Assuming that luminol formed a close-
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packed monolayer at a density of 5.0 x 10
14
 luminol/cm
2
 on the outer surface (πd2) of a GNP, it 
can be estimated that there is a maximum of 1,600 luminol molecules on each GNP. Thus the 
equivalent luminol concentration of various GNP-MUA-LUM solutions can be calculated and 
directly compared with free bulk luminol solutions, as shown in Figure 6.8b. The conversion into 
equivalent luminol concentration did not affect the slopes of GNP-MUA-LUM in the log-log 
scale. For the bulk luminol solutions, the slope at low concentration was 0.040, almost the same 
as 0.035 for GNP-MUA-LUM. But the slope at high concentrations became 1.00, indicating that 
the CL signal was ideally proportional to the bulk luminol concentration. At high concentrations, 
the value of ΔI for the GNP-MUA-LUM is notably higher than that of the bulk luminol solution 
at the same equivalent concentration. The higher CL signal, smaller slope, and lower background 
made the cross point for GNP-MUA-LUM appear at a lower concentration (~3.0 x 10
-11
 M 
equivalent luminol) than that of the bulk luminol solutions (3.9 x 10
-10
 M). Thus luminol-labeled 
GNPs provided a detection limit that was about one order of magnitude lower than in bulk 
solutions. Since it is unlikely that luminol can form a perfect close-packed monolayer on GNPs, 
the real detection limit could be even lower. 
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Figure 6.10 Calibration curves of the background-subtracted chemiluminescence signal vs. the 
concentration of [Fe(CN)6]
3-
 catalyst using luminol-attached GNPs (GNP-MUA-LUM) and bulk 
luminol solution, respectively. In the experiments with bulk luminol solutions, 25 µL of 0.10 M 
NaOH, 25 µL of 1.41 M H2O2, and 25 µL of K3Fe(CN)6 solution at varied concentrations were 
preloaded in a 96-well plate. Then 25 µL of luminol solution at 1.0 x 10
-6
 M concentration was 
added by a micro-injector into the above mixed solution to initialize the CL reaction. In the 
experiments with suspended GNP-MUA-LUM solutions, 25 µL of 0.10 M NaOH, 25 µL of 1.41 
M H2O2 and 25 µL of GNP-MUA-LUM solution at 1.0 x 10
11
 GNP/mL concentrations 
(equivalent to 2.7 x 10
-7
 M luminol concentration) were preloaded in the wells of a 96 well plate. 
Then 25 µL of K3Fe(CN)6 solution at varied concentrations was added by the micro-injector into 
the well to start the CL reaction. The error bars of the data with bulk luminol solutions are 
standard deviations calculated from three measurements at each condition. 
Some analytical applications may use Scheme II (see Figure 6.2) in which the catalyst 
concentration such as [Fe
3+
] is measured by supplying sufficient luminol and other reagents. The 
representative calibration curves in using 1.0 x 10
-6
 M bulk luminol and 1.0 x 10
11
 GNP-MUA-
LUM nanoparticles/mL (equivalent to 2.7 x 10
-7
 M luminol) as the CL reagent are presented in 
Figure 6.10. In the CL measurements with bulk luminol solutions, a linear curve on the log-log 
scale was observed with a slope of 0.52 in the range of 1.0 x 10
-9
 M to 1.0 x 10
-4
 M K3Fe(CN)6. 
The detector was saturated at the K3Fe(CN)6 concentration above 1.0 x 10
-4
 M. Below 1.0 x 10
-9
 
M K3Fe(CN)6, the ΔI signal was buried in the high and noisy background signal (about 3 – 5 
times higher than in Figure 6.8). This was mostly due to trace K3Fe(CN)6 contaminations in the 
tubing and injector from previous experiments. Premixing K3Fe(CN)6 with NaOH and H2O2 
solutions in the wells and adding the luminol solution through the micro-injector instead slightly 
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lowered the background, but it was still not possible to reach the extremely low background as in 
the case of luminol as the analyte.    
A similar calibration curve of ΔI vs. the K3Fe(CN)6 concentration was obtained using the 
GNP-MUA-LUM solution (1.0 x 10
11
 nanoparticles/mL) and the result is summarized in Figure 
6.10. The equivalent luminol concentration (2.7 x 10
-7
 M) was lower than the bulk luminol 
solution (1.0 x 10
-6
 M) and thus the detection saturation at high K3Fe(CN)6 concentrations was 
avoided. The background at low K3Fe(CN)6 concentrations was reduced by ~2 times. The slope 
of the linear curve at high K3Fe(CN)6 concentrations was increased from 0.52 (for the bulk 
luminol solution) to 0.76 (for the GNP-MUA-LUM solution). However, the linear range with the 
GNP-MUA-LUM solution was shifted to ~100 to 1,000 fold higher K3Fe(CN)6 concentrations 
comparing to the bulk luminol solution. The detection limit of K3Fe(CN)6 concentration 
(represented by the cross points) was 8.2 x 10
-10
 M for bulk luminol and 5.6 x 10
-7
 M for GNP-
MUA-LUM, respectively. The reason for lower CL signal with GNP-MUA-LUM in Figure 6.10 
may be due to two factors: (1) lower equivalent luminol concentration used in these  
experiments, and (2) the lower diffusion coefficient of GNPs than free luminol molecules 
causing lower CL reaction rate when the K3Fe(CN)6 concentration was low. However, since the 
slope with GNP-MUA-LUM is larger, it is expected that the CL signal in GNP-MUA-LUM 
could be higher, at least at the high K3Fe(CN)6 concentration limit, if a higher GNP-MUA-LUM 
concentration could be used. However, we found that increasing GNP-MUA-LUM concentration 
often induced GNP aggregation and precipitation to the bottom of the wells. These GNPs were 
out of the focal zone of the detector and thus caused the CL signal to decrease and unreliable. 
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Figure 6.11 Log-log graph of ΔI vs. the number of particles. Red square: GNP-MUA-LUM. 
Green dot: luminol functionalized latex beads (Latex bead-LUM). 
Comparison of the CL measurement using GNP-MUA-LUM and luminol functionalized 
latex beads (latex bead-LUM) was shown in Figure 6.11. It showed that chemiluminescence can 
detect down to ~1000 latex beads. Using the same amount of GNPs and latex beads, the 
chemiluminescence intensity by using latex beads is about 3 orders of magnitude larger than that 
by using GNPs. However, the surface area of 30-nm-diameter latex bead is only ~9 times larger 
than that of 10-nm-diameter GNP. The much larger signal might be due to latex bead’s porous 
surface trapped large amount of luminol molecules.  
 6.4 Conclusions 
In conclusion, we have demonstrated that the largely enhanced CL signal can be 
generated with luminol molecules covalently attached to 10-nm-diameter GNPs through an 
alkane thiol linker. This approach may be adopted for ultrasensitive analyses under two different 
schemes depending on whether luminol-labeled GNPs serve as a part of the analyte or as a 
reagent to generate CL for iron-containing catalysts as the analyte. The CL properties of luminol-
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labeled GNPs have been systematically studied in suspended solutions in 96-well plates. The CL 
signal can be observed over 8 orders of magnitude variations in GNP concentration. The log-log 
calibration curves of suspended GNP-MUA-LUM showed two linear responses with distinct 
slopes. The portion with high slope can be used for reliable quantitative analysis and the portion 
with small slope may be used for ultrasensitive screening. It has been also found that using the 
same number of particles, luminol functionalized latex beads (30 nm diameter) showed about 3 
orders of magnitude higher CL intensity compared to 10-nm-diameter luminol-labeled GNPs. 
Hybridization of HA target on the latex beads and HA probe on the glass slide or optical fiber 
surface has been successfully achieved. However, the density of latex beads on the optical fiber 
surface needs to be greatly improved in order to achieve ultrasensitive detection of viral nucleic 
acid. Finally, this assay will be incorporated into a simple hand-held device for routine assays in 
hospitals and clinics or for large-scale screening of human populations as diagnostic tools to 
identify specific viral strains.  
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Chapter 7 - Conclusions and Future Plan 
In this dissertation, nanoelectrodes and nanoparticles have been used to develop 
biosensors for cancer-related proteases and viral nucleic acid detection, respectively. Our goal is 
to develop simple and portable devices for point-of-care detection of cancer and blood-borne 
pathogens. We hope that our results from these projects could pave the way of utilizing 
nanotechnology to achieve device miniaturization and multiplex detection.  
 7.1 Electrochemical protease biosensor based on enhanced AC voltammetry 
using CNF NEAs  
In this study, continuously repeated ACV measurement of Fc-tetrapeptide attached to 
VACNF NEAs has been proved to be a reliable tool to measure the proteolytic kinetics and 
quantify the protease activity in both purified enzyme form and complex lysates environment. 
Significantly, the activity of cathepsin B measured by this electrochemical method was found to 
increase from normal to cancer cell lysates. In addition, the clear inhibitor effects indicated that 
this method may be used as an effective technique for inhibitor screening in the complex 
biological samples. This study demonstrates the feasibility for future protease profiling using a 
library of peptide substrates specific to interested proteases on independently addressed NEAs. It 
could be potentially developed into a portable multiplex electronic system for cancer diagnosis, 
assessment of treatment efficacy, and drug screening. 
In the future, detection of cathepsin B activity can also be studied by using QCM and 
EIS. The results from above methods should be compared with those from ACV method in order 
to prove the validity of ACV method in the application of cathepsin B activity detection. In 
addition, quantifying the concentration of active cathepsin B in the cancer cell lysates by using 
ELISA method is also needed in the future to validate the results from ACV method. Moreover, 
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in the study of inhibitor GC-373 effect on cathepsin B activity, a complete IC50 curve can be 
generated by using EC method, which can help to demonstrate that this ACV method on VACNF 
NEAs is a suitable technique to develop inhibitor screening. Finally, by using e-beam patterned 
NEAs, a library of peptides can be immobilized on each independently address NEA to realize 
protease profiling.  
 7.2 Ultrasensitive blood-borne pathogen biosensor based on CL method 
   
Figure 7.1 (a) Melted PMMA optical fiber tip formed a bulb. (b) The light enters the bulb and 
travels through the optical fiber. (c) Scheme of the portable chemiluminescence readout for 
detection of virus through nucleic acid hybridization on optical fibers. 
We have demonstrated that the largely enhanced CL signal can be generated with luminol 
molecules covalently attached to 10-nm-diameter GNPs through an alkane thiol linker or 
luminol-labeled 30-nm-diameter latex beads. We found that using the same number of particles, 
luminol-labeled 30-nm-diameter latex beads showed even higher CL intensity compared to 10-
nm-diameter luminol-labeled GNPs. Hybridization of HA target on the latex beads and HA 
probe on the glass slide or optical fiber surface has also been successfully achieved from the 
results of fluorescence optical microscope and SEM images.  
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However, the density of latex beads on the optical fiber surface through DNA 
hybridization needs to be greatly improved. This might be achieved by finding an appropriate 
etching method to generate uniform and abundant –OH groups on the surface of the optical 
fibers. By annealing the PMMA optical fiber tip into a sphere, the optical fiber can capture the 
photons from every direction (Figure 7.1a&b). Thus, the sensitivity can be further improved. In 
the future, we will be able to functionalize H1N1 viral nucleic acid probe 1 on the spherical tip 
of the optical fiber and after inserting the optical fibers into the fluids containing target viral 
nucleic acid, the probe 1 will hybridize with this target. Then, the hybridization of nucleic acid 
probe 2 with target will be performed. Probe 2 and luminol molecules are co-immobilized on the 
surface of the carrier nanoparticles (Figure 7.1c). The concentration of the viral nucleic acid will 
be determined from the intensity of the chemiluminescence due to luminol molecules. Assays 
will be incorporated into a simple hand-held device for routine assays in hospitals and clinics or 
for large-scale screening of human populations as diagnostic tools to identify specific viral 
strains.  
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Appendix A - Supporting Information for Chapter 2&3 
 
Figure A.1 Field-emission scanning electron microscopy image at 45° perspective view shows 
that VACNFs of ~150 nm in average diameter are encapsulated in SiO2 matrix leaving only the 
tips exposed.  
 
Figure A.2 The ACV of H2N-(CH2)4-CO-Leu-Arg-Phe-Gly-NH-CH2-Fc immobilized on the 
GCE (a) from the initial measurement and (b) from the measurement after 20 minutes. The AC 
frequency was 30 Hz and the amplitude was 25 mV. The measurement was done in 250 µL of 25 
mM MES solution (pH 5.0).  
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Figure A.3 Comparison of AC voltammograms (ACVs) of H2N-(CH2)4-CO-Ala-Ala-Asn-Leu-
NH-CH2-Fc immobilized on a macroscopic glassy carbon electrode (GCE) (a–c) and a VACNF 
NEA (d–f) at the AC voltage amplitude of 0.05, 0.35 and 0.5 V. All the measurements were done 
in 500 μL of 50 mM MES (pH 5.0) and 250 mM NaCl. Sinusoidal waves with fixed frequency of 
40 Hz for GCE and frequency of 1750 Hz for CNF NEA were superimposed on a DC staircase 
ramp from -0.05 to 0.65 V at a scan rate of 10 mV/s. The measured average AC current at each 
point was normalized by the 7.1 mm
2
 geometric surface area defined by the 3-mm i.d. O-ring. 
The real CNF surface area is ~100 times less. 
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Figure A.4 (a) Background-corrected ACV peak current density ip,acv (normalized to the 7.1 mm
2
 
geometric electrode area) of  H2N-(CH2)4-CO-Leu-Arg-Phe-Gly-NH-CH2-Fc immobilized on a 
VACNF NEA plotted against the logarithm of the frequency. (b) Background-corrected ACV 
peak current density ip,acv (normalized to the 7.1 mm
2
 geometric electrode area) of  H2N-(CH2)4-
CO-Leu-Arg-Phe-Gly-NH-CH2-Fc immobilized on a VACNF NEA plotted against the 
amplitude. All the measurements were done in 250 μL of 25 mM MES (pH 5.0). Note: The real 
CNF surface area is ~100 times less than the geometric surface area defined by the O-ring. 
         
Figure A.5 Negative control experiments. The change of the peak current (ip,acv) of H2N-(CH2)4-
CO-Leu-Arg-Phe-Gly-NH-CH2-Fc immobilized on a VACNF NEA in continuously repeated 
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ACV measurements while (a) 25 μL of activation buffer consisting of 5 mM DTT and 25 mM 
MES (pH 5.0) and (b) the same buffer containing 9.8 ng µL
-1
 (338 nM) deactivated cathepsin B 
were added into the electrochemical cell containing 250 μL of 25 mM MES (pH 5.0). All ACV 
measurements were carried out at f = 800 Hz and AC voltage amplitude V0 = 150 mV. 
     
 
Figure A.6 (a) The kinetic curves of the fluorescence intensity of 0.1 ng µL
-1
 (3.45 nM) 
cathespin B reacting with different concentrations of substrate Z-Leu-Arg-AMC in 25 mM MES 
(pH 5.0). The cleavage between Arg and AMC released free AMC products which were strongly 
fluorescent and gave the increased fluorescence intensity. Inset: calibration curve of the 
fluorometer. (Excitation wavelength: 365 nm, emission wavelength: 410–460 nm) (b) The 
calibrated concentration of free AMC product during cathepsin B cleavage of various 
concentrations of substrate Z-Leu-Arg-AMC.  
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Figure A.7 (a) The initial proteolysis reaction rate vi of cathepsin B plotted against the starting 
concentration of the substrate Z-Leu-Arg-AMC. The reaction rate was calculated from the slope 
of the tangent of the initial segment of the curves shown in Figure S8b. (b) Replot of the data 
presented in (a) and derivation of various catalytic constants. The value of kcat/Km for cathepsin 
B was calculated as 2.3 x 10
4
 M
-1
s
-1
. 
 
Figure A.8 Negative control experiments for legumain proteolysis. The change of the peak 
current (ip,acv) of H2N-(CH2)4-CO-Ala-Ala-Asn-Leu-NH-CH2-Fc immobilized on a VACNF 
NEA in continuously repeated ACV measurements (a) while 11 μL of activation buffer 
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consisting of 50 mM CH3COONa (pH = 4.0, adjusted by adding acetic acid) and 100 mM NaCl 
was added into the electrochemical cell containing 250 μL of 50 mM MES (pH 5.0) and 250 mM 
NaCl; (b) similar experiments by including 90.9 ng µL
-1
 (1.90 μM) deactivated legumain in the 
activation buffer. All ACV measurements were carried out at f = 1750 Hz and AC voltage 
amplitude V0 = 150 mV. 
 
Figure A.9 (a) The fluorescence intensity curves of 0.5 ng µL
-1
 (10.2 nM) legumain reacting 
with different concentration of substrate Z-Ala-Ala-Asn-AMC in the assay buffer consisting of 
50 mM MES (pH 5.0) and 250 mM NaCl. Inset: calibration curve of the fluorometer. (excitation 
wavelength: 365 nm, emission wavelength: 410–460 nm). (b) The calibrated free AMC product 
concentration during legumain cleavage the substrate Z-Ala-Ala-Asn-AMC.  
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Figure A.10 (a) The initial proteolysis reaction rate vi of legumain plotted against the 
concentration of the substrate Z-Ala-Ala-Asn-AMC. The reaction rate was calculated from the 
slope of the tangent of the initial segment of the curves shown in Figure S11b. (b) Replot of the 
data presented in (a) and the derivation of various catalytic constants. The value of kcat/Km for 
legumain was calculated as 4.3 x 10
3
 M
-1
s
-1
.  
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Figure A.11 (a) HPLC chart of H2N-(CH2)4-CO-Leu-Arg-Phe-Gly-NHCH2Fc in 25 mM MES 
(pH 5.0) buffer. The tetrapeptide appeared at 9.4 minute in the HPLC chart and its structure was 
verified by mass spectrometry analysis. (b) HPLC chart of Phe-Gly-NHCH2Fc in 25 mM MES 
(pH 5.0) buffer. The dipeptide appeared at 6.7 minute in the HPLC chart and its structure was 
verified by mass spectrometry analysis. (c) HPLC chart of 6.35 mM H2N-(CH2)4-CO-Leu-Arg-
Phe-Gly-NHCH2Fc in 25 mM MES (pH 5.0) buffer incubated with 4.95 ng μl
-1
 (0.17 μM) 
cathepsin B for 2 hours. Absorbance peak at 6.7 minute was collected and lyophilized and mass 
spectrometry analysis showed it to be Phe-Gly-NHCH2Fc. HPLC Method: a gradient elution 
from 10% to 50% of acetonitrile in 0.1 M phosphate buffer (pH = 6) over 40 minutes was used 
with a flow rate of 10 ml/min and detection wavelength λ at 254 nm.  The column is Xperchrom 
AEGIS C18 120A 10 μm (Phenomenex). 
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Figure A.12 (a) HPLC chart of H2N-(CH2)4-CO-Ala-Ala-Asn-Leu-NHCH2Fc in 50 mM MES 
(pH 5.0) and 250 mM NaCl. The tetrapeptide appeared at 9.7 minute in the HPLC chart and its 
structure was verified by mass spectrometry analysis. (b) HPLC chart of Leu-NHCH2Fc in 50 
mM MES (pH 5.0) and 250 mM NaCl. The Leu-NHCH2Fc appeared at 12.2 min in the HPLC 
chart and its structure was verified by mass spectrometry analysis. (c) HPLC chart of 100 μM 
H2N-(CH2)4-CO-Ala-Ala-Asn-Leu-NHCH2Fc in 50 mM MES (pH 5.0) and 250 mM NaCl 
incubated with 98.7 ng/µL (2.01 μM) legumain for 2 hours. Absorbance peak at 12.2 min was 
collected and lyophilized and mass spectrometry analysis showed it to be Leu-NHCH2Fc. HPLC 
Method: a gradient elution from 10% to 50% of acetonitrile in 0.1 M phosphate buffer (pH=6) 
over 40 minutes was used with a flow rate of 10 ml/min and detection wavelength λ at 254 nm.  
The column is Xperchrom AEGIS C18 120A 10 μm (Phenomenex). 
 
Figure A.13 Comparison of cyclic voltammetric measurements of H2N-(CH2)4-CO-Ala-Ala-
Asn-Leu-NHCH2-Fc immobilized on (a) a macro-GCE and (b) a VACNF NEA. The 
measurements were carried out at the scan rate of 50 mV s
-1
 in 1 mL of 1.0 M KCl. 
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Figure A.14 Preliminary specificity testing result. The change of the peak current (ip,acv) of H2N-
(CH2)4-CO-Ala-Ala-Asn-Leu-NH-CH2-Fc immobilized on a VACNF NEA in continuously 
repeated ACV measurements while 9.8 ng µL
-1
 (338 nM) activated cathepsin B in 25 μL of 
activation buffer consisting of 5 mM DTT and 25 mM MES (pH 5.0) was added into the 
electrochemical cell containing 250 μL of 25 mM MES (pH 5.0). 
        
 
Figure A.15 (a) The change of the peak current (ip,acv) of octapeptide H2N-(CH2)4-CO-Pro-Ala-
Ala-Asn-Leu-Ile-Arg-Leu-NH-CH2-Fc immobilized on a VACNF NEA in continuously repeated 
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ACV measurements while 90.9 ng µL
-1
 (1.90 µM) legumain in the activation buffer consisting of 
50 mM CH3COONa (pH = 4.0, adjusted by adding acetic acid) and 100 mM NaCl was added 
into the electrochemical cell containing 250 µL of 50 mM MES (pH 5.0) and 250 mM NaCl. 
ACV measurements were carried out at f = 1750 Hz and AC voltage amplitude V0 = 150 mV. (b) 
Replot of the data presented in figure (a) showing the reduction of the quantity of surface 
adsorbed Fc (i.e. surf) during enzymatic cleavage of the octapeptide after adding the legumain. 
(c) Plot of the reaction rate (vi) versus the quantity of surface adsorbed Fc (surf) during the 
enzymatic reaction. 
Verification of the inactivity of the guanidine NH function of arginine residue of Boc-HN-
(CH2)4CO-Leu-Arg-Phe-Gly-NHCH2-Fc.   
The following reaction has been carried out to verify that the guanidine NH function of arginine 
residue of Boc-HN-(CH2)4CO-Leu-Arg-Phe-Gly-NHCH2-Fc does not form amide bond with the 
carboxylic function on carbon nanofibers. To a 1 mL aqueous solution of Boc-HN-(CH2)4CO-
Leu-Arg-Phe-Gly-NHCH2-Fc (3 mg, 3.4 μmol), benzoic acid (0.4 mg, 3.4 μmol), and N-
hydroxysuccinimide (0.4 mg, 3.4 μmol) was added with 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride (0.66 mg, 3.4 μmol), and the resulting 
solution was stirred at room temperature for 2 hours. Mass spectrometry analysis showed that no 
reaction took place between the NH group of arginine residue and the carboxylic acid moiety of 
benzoic acid. Boc-HN-(CH2)4CO-Leu-Arg-Phe-Gly-NHCH2-Fc remained unchanged.  The test 
suggested that the NH moieties in the side chain of arginine residue does not react with the 
carboxylic acid function of carbon nanofibers. The most likely route for the peptide to be 
attached to the VACNF NEA is by forming the amide bond through the –NH2 group at the distal 
end of the linker.  
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Appendix B - Supporting Information for Chapter 4 
 
Figure B.1 Bright field microscope images of patterned VACNF NEAs with (a) using a 4x 
objective lens, (b) and (c) using a 50x objective lens. (d) Field-emission scanning electron 
microscopy image at 45° perspective view of the patterned VACNF NEAs. The scale bars are 
500, 50, 50, and 1 m, respectively. 
(a) 
(b) (c) 
(d) 
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Table B.1 The fitting parameters of the ACV signal ip,acv vs. the reaction time t corresponding to 
Fig. 1E–G after the cathepsin B solution at different concentrations were added to the 
electrochemical cell. 
[Cathepsin B] 
(nM) 
Fitting Equation: c  b  )/exp( 0t  ttii   
 i0 (A) b (A/s) c (A) (s) 
15.5 6.69 x 10
-7
 -4.12 x 10
-11
 8.11 x 10
-7
 2935 
30.7 8.35 x 10
-7
 -3.33 x 10
-11
 1.03 x 10
-7
 1287 
62.1 7.22 x 10
-7
 -4.55 x 10
-11
 4.35 x 10
-7
 448 
 
      
Figure B.2 ACV of a random VACNF NEA after being soaked in the solution of 1.0 mM H2N-
(CH2)4-CO-Leu-Asn-Phe-Gly-NH-CH2-Fc for 2 hr.  
  
145 
 
     
Figure B.3 Negative control experiments. (A) activated cathepsin B added to non-relevant 
tetrapeptide substrate H2N-(CH2)4-CO-Ala-Ala-Asn-Leu-NH-CH2-Fc. (B) activated cathepsin B 
added to modified tetrapeptide H2N-(CH2)4-CO-Leu-Asn-Phe-Gly-NH-CH2-Fc where the 
cleavage site Arg was replaced with Asn. All tetrapeptides were covalently attached to the 
exposed CNF tips in random VACNF NEAs and the proteolyses were measured with 
continuously repeated ACV measurements. In (A) and (B), 25 μL of 9.8 ng·µL-1 (338 nM) 
activated cathepsin B in the activation buffer consisting of 5 mM DTT and 25 mM MES (pH 
5.0) was added into the electrochemical cell containing 250 μL of 25 mM MES (pH 5.0). The 
final cathepsin B concentration was 30.7 nM. ACV measurements were carried out at f = 800 Hz 
with the AC voltage amplitude V0 = 150 mV.  
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Table B.2 Comparison of kcat/KM values of cathepsin B from literatures and our electrochemical 
method.  
Methods Substrate Resources kcat/KM (M
-1
s
-1
) 
ACV H2N-(CH2)4-CO-L-R-F-G-NH-CH2-Fc Our manuscript (3.68 ± 0.05) × 10
4
 
Fluorescence Z-L-R-AMC R & D system 1.2 × 10
5
 
FRET Abz-GIVRAK(Dnp)-OH Anal. Biochem. (2004), 
335(2), 244-252. 
7.288 × 10
6
  
 
Fluorescence Abz-FSQPMKRLTLGNTTQ-EDDnp 
 
Hypertension (2000), 35(6), 
1278-1283. 
7.5 × 10
4
  
 
Fluorescence Abz-AFRSAAQ-EDDnp Biochem. (1997), 36(41), 
12608-12615. 
(1.95 ± 0.05) × 10
3
  
 
Fluorescence Abz-QVVAGA-EDDnp Biochem. (1997), 36(41), 
12608-12615. 
(3.0 ± 0.2) × 10
4
 
 
Fluorescence Cbz-FR-AMC 
 
Biochem. (1997), 36(41), 
12608-12615. 
(4.25 ± 0.3) × 10
5
 
 
Fluorescence Boc-Val-Leu-Lys-AMC 
 
J. Agri. & Food Chem. (1996), 
44(3), 774-8. 
1.5 × 10
6
  
 
Fluorescence Abz-QVVA-EDDnp Protein. Chem. (1995) 14, 
645-653 
2.4 × 10
4
 
Fluorescence Abz-QVVAG-EDDnp Protein. Chem. (1995) 14, 
645-653 
2.5 × 10
4
 
Fluorescence Abz-QVVAGG-EDDnp Biochem. J. (1996), 313(3), 
951-6. 
6 × 10
3
 
Fluorescence Abz-QVVAGP-EDDnp Biochem. J. (1996), 313(3), 
951-6. 
5 × 10
3
 
Fluorescence Abz-LVGGP-EDDnp Biochem. J. (1996), 313(3), 
951-6. 
1.7 × 10
4
 
Fluorescence Abz-VVGGP-EDDnp Biochem. J. (1996), 313(3), 
951-6. 
5.4 × 10
4
 
Fluorescence  J. Enzyme Inhibition (1992), 
6(3), 181-94. 
5 × 10
3
 
 
Fluorescence Z-F-R-pNA 
 
Biochem. J. (1992), 285(2), 
427-34. 
(5.460 ± 0.116) × 10
4
 
Fluorescence Z-R-R-pNA 
 
Biochem. J. (1992), 285(2), 
427-34. 
(1.480 ± 0.069) × 10
4
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Figure B.4 The kinetic curve of the fluorescence intensity of 50 μL of 0.48 mg·mL-1 activated 
human breast whole tissue lysate (adult normal) reacting with 50 μL of 100 μM peptide substrate 
Z-Leu-Arg-AMC in 25 mM MES (pH 5.0). The final tissue lysate concentration was 0.24 
mg·mL
-1
. 
 
Figure B.5 The kinetic curve of the fluorescence intensity of 0.25 mg·mL
-1
 human breast whole 
tissue lysate (adult normal) spiked with different concentrations of activated purified cathepsin B 
reacting with 100 μM substrate Z-Leu-Arg-AMC in 25 mM MES (pH 5.0). The final purified 
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cathepsin B concentrations were 0 µg·mL
-1
 (light green), 0.35 µg·mL
-1
 (11.9 nM) (blue) and 
0.70 µg·mL
-1
 (23.9 nM) (red), respectively. 
 
Figure B.6 (a) CV of the patterned VACNF NEAs on each single microelectrode pads. (b) CV 
of patterned VACNF NEAs with all nine microelectrode pads connected together. The 
measurements were done in 50 mM K3Fe(CN)6 and 1.0 M KCl electrolyte at a scan rate of 50 
mV·s
-1
. (c) The average ACV curve from the regular VACNF NEA on a single 200 m x 200 
m microelectrode pad with the tetrapeptide H2N-(CH2)4-CO-Leu-Arg-Phe-Gly-NH-CH2-Fc 
covalently functionalized on the exposed CNF tips. The electrochemical cell was filled with 250 
µL of 25 mM MES (pH 5.0). (d) Four representative background-subtracted ACV curves 
measured at 0 (black), 20 (red), 40 (blue) and 60 min (green) after 25 µL of activated purified 
cathepsin B was added into the electrochemical cell. The final concentration of cathepsin B in 
(a) 1 
 
(b) 
(c) 1 
 
(d) 
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the cell was 30.7 nM (0.9 ng·μL-1). All ACV measurements were carried out at f = 800 Hz and 
AC voltage amplitude V0 = 150 mV. 
 
Figure B.7 (a) The kinetic ACV peak current ip,acv of H2N-(CH2)4-CO-Leu-Asn-Phe-Gly-NH-
CH2-Fc functionalized at the patterned VACNF NEA on a single 200 m x 200 m 
microelectrode pad versus the reaction time after 30.7 nM cathepsin B was added into the 
electrode chemical cell. (b) ACV from an e-beam patterned VACNF NEA on a single 
microelectrode pad which was soaked in 1.0 mM H2N-(CH2)4-CO-Leu-Asn-Phe-Gly-NH-CH2-
Fc solution for 2 hr without forming covalent bonds. The faradaic signal from the physically 
trapped Fc moieties was significant. 
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Appendix C -  Supporting Information for Chapter 5 
Cell lines and correlation with cancer stages 
The selected cell lines were used in representing different stages of cancer formation. 
Human mammary epithelial cells (HMEC), obtained from Lonza (Annandale, NJ, USA), are 
primary cells, derived from adult female breast tissue. HMECs are positive for cytokertins 14 
and 18 and negative for cytokeratin 19. MCF-10A cell line, obtained from American Type Cell 
Culture (ATCC) (Manassas, MA, USA), is a non-tumorigenic epithelial cell line derived from a 
36 year old female. These cells have no signs of terminal differentiation or senescence. They 
respond to insulin, epidermal growth factor (EGF), and glucocorticoids. T47D cell line, obtained 
from ATCC, was isolated by I. Keydar from a pleural effusion obtained from a 54 year old 
female patient with an infiltrating ductal carcinoma of the breast. MDA-MB-231 cell line, 
obtained from ATCC, was isolated from a metastatic site of a 51 year old female patient with 
breast adenocarcinoma. 
Western blot and immunoprecipitation of cancer cell lysates  
Cells were harvested and lysed in lysis buffer (20 mM Tris pH 7.5, 0.5 mM EDTA, 0.5 
mM EGTA, 0.5% Triton X-100) at 1:1,000 dilution of protease inhibitors (Sigma-Aldrich, Saint 
Louis, MO, USA). Whole-cell extract (25 μg) was resolved by 10% SDS-PAGE and transferred 
to nitrocellulose membrane (Midwest Scientific, Saint Louis, MO, USA) that was blocked in 5% 
milk for an hour at room temperature and then incubated with monoclonal antibodies (1:1,000). 
Western blots were detected by enhanced chemiluminescence detection reagents (Pierce, 
Rockford, IL, USA) and visualized by Fluorchem E imaging system (ProteinSimple, Santa Clara, 
CA, USA). 
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The procedure for obtaining whole-cell extract (WCE) for immunoprecipitation (IP) was 
the same as that in Western blotting. First, 500 μg WCE was pre-cleared with 20 µL of protein 
A/G-agarose beads from Santa Cruz Biotechnology (Santa Cruz, CA, USA) for 30 minutes. 
Then, the mixture was centrifuged at 2,000 rpm for 5 minutes. The supernatant was collected and 
incubated with the primary antibody of cathepsin B (1:1000, giving the total amount of 1.4 µg) 
from Santa Cruz Biotechnologies (Santa Cruz, CA, USA) overnight at 4ºC. Twenty µl of protein 
A/G-agarose beads was added and incubated for additional 2 h at 4ºC on a rocker. Samples were 
centrifuged at 2,000 rpm for 5 minutes and pellet (A/G-agarose complex) was washed three 
times with lysis buffer (20 mM Tris pH 7.5, 0.5 mM EDTA, 0.5 mM EGTA, 0.5% Triton X-
100). Samples were run on 10% SDS-PAGE and immunoblotted with cathepsin B as described 
in Western blot analysis. In case of multiple steps of IP, samples were incubated with cathepsin 
B antibodies for 2 or 3 times prior to Western blot analysis. This repeated step allows the 
complete removal of cathepsin B in whole cell lysate. Intensities of the bands were digitized 
using Un-Scan-It software (Silk Scientific Inc., Orem, Utah, USA). The supernatant after the IP 
procedure was used in some proteolysis experiments as a blank control. 
 
152 
   
Figure C.1 Western blot analysis of actin in four types of breast cell lysates.  Whole cell extract 
and supernatant after three rounds of immunoprecipitation showed a detection of actin at 43 kDa. 
Table C.1 Integrated pixel intensity obtained from Western blot of 0.5 mg pellet collected from 
immunoprecipitation of the whole cell extracts. The proenzyme cathepsin B is ~ 37 kDa and the 
active cathepsin B is ~ 25 kDa.  
 Integrated Pixel Intensity 
Cell Line 37 kDa 25 kDa Total 
HMEC 1766956 1293768 3060724 
MCF-10A 1778380 1291818 3070198 
T47-D 1765820 1589108 3354928 
MDA-MB-231 2701916 1137183 3839099 
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Figure C.2 (a) Western blot of different amount of purified recombinant cathepsin B using 1.4 
µg of cathepsin B antibody. The proenzyme cathepsin B is ~ 37 kDa and the active cathepsin B 
is ~ 25 kDa. (b) Plot of integrated pixel intensity from both bands versus the amount of cathepsin 
B.   
                         
(a) 
(b) 
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Figure C.3 The kinetic curves of the fluorescence intensity during proteolysis of Z-Leu-Arg-
AMC in 25 mM MES (pH 5.0) with 0.05 ng·μL-1 purified cathepsin B after (1) normal activation 
procedure by incubation in activation buffer 15 min (blue triangle); (2) normal activation 
followed by 30 min additional incubation (black square); and (3) adding 0.6 µM inhibitor GC373 
during the 30 min additional incubation period (red dot). The final concentrations of the substrate 
are 50 µM and all incubation was at room temperature. 
 
                            
Figure C.4 (a) The kinetic curves of the fluorescence intensity during proteolysis of 50 μM Z-
Leu-Arg-AMC in 25 mM MES (pH 5.0) with 0.05 ng·μL-1 purified cathepsin B which inhibited 
by inhibitor GC-373 in different concentrations.  The final concentrations of the inhibitor are 
varied from 0 to 36 μM. (b) IC50 curve of the inhibitor GC-373. The vertical axis represents the 
(a) 
(b) 
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fluorescence intensity (in relative light unit) at 120 min at each inhibitor concentration. The IC50 
value of GC-373 was determined to be 9.7 nM by fitting the IC50 curve with the dose response 
function y = A1 + (A2 – A1)/(1 + 10^((LOGx0 – x)*p)), where the fitting parameter LOGx0 
represents the value of log(IC50). 
 
Figure C.5 The kinetic curves of the fluorescence intensity during proteolysis of Z-Leu-Arg-
AMC in 25 mM MES (pH 5.0) with 0.05 mg·mL
-1
 human mammary epithelial cells (HMEC), 
transformed breast cells (MCF-10A), breast cancer cells (T47D and MDA-MB-231). The final 
concentrations of the substrate are 25 µM (black), 50 µM (red) and 100 µM (blue), respectively.  
(a) (b) 
(c) (d) 
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Figure C.6 (a) Western blot analysis of cathepsin B expression in four types of breast cells: 
Normal breast cells (HMEC), transformed breast cells (MCF-10A), breast cancer cells (T47D), 
and metastatic breast cancer cells (MDA-MB-231). The first column shows that the whole cell 
extract (WCE) of all 4 types of cells consist both proenzyme (~ 37 kDa) and active (~ 25 kDa) 
cathepsin B. (Note that the experimental conditions were varied and thus this set of data is only 
for qualitative assessment). About 0.5 mg of WCE was used for immunoprecipitation (IP) assay 
with 1.4 µg of cathepsin B antibody. The immunoprecipitated fraction was subjected to Western 
blot analysis using cathepsin B antibody. Pellet includes pulldown complex with cathepsin B 
antibody. Supernatant with one round of immunoprecipitation denotes as 1X and supernatant 
with two and three rounds of immunoprecipitation denotes as 2X and 3X, respectively. (b) The 
quantitative cathepsin B expression represented by the total integrated pixel intensity of 
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cathepsin B bands in a set of Western blot analyses under the same conditions from the same 
HMEC, MCF-10A, T47D, and MDA-MB-231 cell lysate loading. The cathepsin B level 
increased in cancer cell lysates.  
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Appendix D - ELISA Results of Breast Cell Lysates 
Quantikine
®
 ELISA kit of human pro-cathepsin B was purchased from R&D systems 
(Minneapolis, MN, USA).  
 
Figure D.1 Calibration curve of absorbance vs the concentration of (a) pro-cathepsin B and (c) 
activated cathepsin B. (b) Bar graph of mass percentage of procathepsin B in the breast cell 
lysates from HMEC, MCF-10A, T47D and MDA-MB-231, based on the calibration curve in (a). 
(d) Bar graph of mass percentage of activated cathepsin B in the breast cell lysates from MCF-
10A, T47D and MDA-MB-231, based on the calibration curve in (c).  
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Appendix E - Chemiluminescence Measurement Using Built-in-
House Handheld Luminometer 
All the chemiluminescence experiments using built-in-house luminometer was conducted 
by Dr. Jianwei Liu, Cas LeMaster and Caleb Christainson from professor Judy Wu’s lab in 
Department of Physics and Astronomy, University of Kansas. 
The miniaturized luminometer is comprised of a small metal box (approximately 10 cm x 
20 cm) containing a TEFLON sample well with integrated 30-fiber bundle optical fiber (Figure 
B.1). The sample solution is injected through the opening on the top of the box by a pipette. The 
detector is a head-on PMT for photo counting. The spectral range is from 350 to 650 nm and the 
peak wavelength is at 420 nm. The detection limit of the PMT is 3 x 10
-21
 mol of luciferase or 1 
x 10
-18
 mol of ATP. 
           
Figure E.1 (a) Optical fiber bundle inserts into the opening on the top of the metal dark box to 
collect the photons from the reaction in the TEFLON sample well. (b) The overall view of the 
setup of the built-in-house luminometer.  
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Figure E.2 Calibration curves of the background-subtracted chemiluminescence signal vs. the 
concentration of bulk luminol solution using (a) optical fiber bundles and (b) commercial 
luminometer. 
 
Figure E.3 (a) The kinetic CL measurements with luminol and HA target DNA-attached latex 
beads (latex beads-HA target/LUM) solution at varied concentrations using built-in-house 
luminometer. (b) The background-subtracted chemiluminescence signal vs. the concentration of 
latex beads-HA target/LUM solution. About 50 µL of 0.10 M NaOH, 50 µL of 1.41 M H2O2 and 
50 µL of 1.0 mM K3Fe(CN)6 solution were preloaded in a TEFLON well. Then 50 µL of latex 
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beads-HA target/LUM solution with varied concentration was added using a pipette to initialize 
the CL reaction. The concentration of the stock solution is 4.75 x 10
10 
mL
-1
 (stock HA/LUM). 
Dilution 10
-1 
to dilution 10
-5
 corresponds to concentration from 4.75 x 10
9 
mL
-1
 to 4.75 x 10
5 
mL
-
1
. 
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